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Abstract 
 
Glycosaminoglycans (GAGs) are linear and anionic polysaccharides found in 
extracellular matrices, and are related to several intracellular biological phenomena. 
Their structure is highly heterogeneous in terms of their chain length and modification, 
and this structural diversity is closely related to their biological functions. The structure 
of GAGs is regulated by the biosynthetic mechanisms; hence, a method for evaluating 
the GAG production capability including their biosynthetic intermediates is needed for 
the structure-function relationship studies. -Xylosides have been used artificial 
acceptors for GAG; however, the structures of -xylosides appropriate for investigation 
of GAG intermediates are not yet developed. Therefore, it was the aim of this study to 
discover a -xyloside suitable for in-depth analysis of GAG biosynthetic intermediates 
in cells and to establish a comparative quantification method. The thesis is composed of 
six sections.  
In chapter 1, general information on GAG and the saccharide primer method 
was summarized, and then issues in GAG related bioscience were clarified. 
Additionally, the aim of the study was described. 
In chapter 2, the synthetic scheme for -xylosides that have O-xylosyl amino 
acid residues was established using chemoenzymatic condensation.  
In chapter 3, the priming abilities of the four -xylosides in normal human 
dermal fibroblast (NHDF) cells were examined. By optimization of sample preparation 
and liquid chromatography-tandem mass spectrometry (LC–MS/MS) conditions, an 
analytical method for phosphorylated oligosaccharides was established, and then the 
saccharide primer appropriate for comparative quantification of GAG intermediate was 
determined.  
In chapter 4, a comparative quantification method for elongated 
oligosaccharides using stable-isotope-labeled saccharide primer was established. The 
method was validated using GAG biosynthesis inhibitors. The result indicates that the 
method could clarify differences in the mode of action of the examined GAG inhibitors. 
In chapter 5, the effect of exogenous sulfated GAGs on endogenous GAG 
production was examined by the comparative quantification method. The method 
revealed that certain sulfated GAGs stimulate NHDF cells to increase endogenous GAG 
production. 
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In chapter 6, the results and discussion of the thesis were summarized and the 
perspective of the method established in the thesis was described. 
In the present thesis, the feasibility of saccharide primer method using 
-xyloside for quantitative and qualitative studies for the capability of GAG 
intermediate biosynthesis was demonstrated. The saccharide primer method was applied 
to evaluate the effect of exogenous GAGs on endogenous GAG production. The effect 
of exogenous GAG on endogenous GAG production was successfully confirmed by the 
established method. This method will lead to an understanding of both GAG 
biosynthetic mechanisms and the structure-activity relationship of the GAG, as well as 
drive GAG-based drug discovery. 
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Chapter 1  
General Introduction 
 
1.1 Glycosaminoglycans 
1.1.1 General information 
Glycosaminoglycans (GAGs), linear and anionic polysaccharides that 
comprise of alternative disaccharide units, are main components of extra- and 
pericellular matrices. In accordance with the structure of repeating disaccharide units, 
GAGs are classified into four species, which are hyaluronan (HA), chondroitin 
sulfate/dermatan sulfate (CS/DS), heparan sulfate/heparin (HS/Hep), and keratan sulfate 
(KS). Although GAGs are ubiquitously distributed in tissues and biological fluid, the 
structures found in tissues are widely varied. Details of the classification, structural 
features, and main distribution of the GAGs are summarized in Table 1-1.  
 
Table 1-1 Structural and biological features of glycosaminoglycans.1 
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Except for HA, all GAGs are sulfated on their hydroxyl or amino groups, and 
are bound to core proteins of proteoglycan side chains. The disaccharide units 
composing CS/DS and HS are named in accordance with their sulfated pattern. For 
instance, CS-A unit indicates a -4 glucuronic acid (GlcA) 1-3 N-acetylgalactosamine 
(GalNAc) (4-O-sulfate) 1- structure. The nomenclature of disaccharide units is 
summarized in Figure 1-1. Besides those described above, some minor disaccharide 
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units regarded to have sulfated of 3-O-groups on GlcA residues have been found in 
CS/DS.2 Because of their chain length, disaccharide sequences, and sulfation degrees, 
the GAG chains are basically highly heterogeneous.  
 
1.1.2 Biological activity 
Sulfated GAGs have attracted much interest for several decades because of their 
unique and wide range of biological functions (Figure 1-2); many studies on sulfated 
GAGs have been conducted for drug discovery. Specifically, heparin is one of the most 
investigated GAGs because of its biological function and high potency for therapeutic 
applications such as anti-coagulants. This bioactivity is mainly attributed to the binding 
region for anti-coagulant factors such as antithrombin III (Figure 1-3).3 Moreover, HSs 
are crucially involved with numerous extracellular signaling events such as cell 
development and angiogenesis through various growth factors or cytokines.4,5 For 
example, HS/Hep allows specific interactions with various growth factors and their 
receptors. Association of HS with both fibroblast growth factors (FGFs) and FGF 
receptors (FGFRs) results in an increase in the 1:1 dimer of the FGF–FGFR complex. 
Consequently, HS and heparin can stabilize the FGF-FGFR complex and enhance the 
activation of intracellular signaling pathways.6,7 
 
 
 
 
Figure 1-1 The structure of CS disaccharide units. The presented disaccharide unit is an unsaturated
disaccharide obtained by CS lyase digestion. 
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CS and DS are also known to contribute to various biological events through 
non-covalent interaction with growth factors, cytokines, chemokines, morphogens, and 
small molecules. For example, highly sulfated CSs such as CS-E have been 
demonstrated to bind to various growth factors such as epidermal growth factors (EGF), 
FGFs, platelet–derived growth factor (PDGF), vascular endothelial growth factor 
(VEGF), and transforming growth factor  (TGF).8 Moreover, CSs can associate with 
microbial pathogens.9–11 These interactions are due to the sulfated degrees and the 
sulfated positions and sequences; hence, the characterization of the mechanism of 
Figure 1-3 Heparin pentasaccharide structure for AT III binding. 
Figure 1-2 Multiple roles of GAGs in biological events. 
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CS-protein interactions is an issue that needs to be solved in order to understand the 
biological meaning of the structural variation of the CS chain. 
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Table 1-2 Some of the putative molecular interactions exhibited by GAGs.12 
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1.1.3 Biosynthesis 
Biosynthesis of polysaccharides, known as the third life chain followed by 
DNA and proteins, are not dictated by the central dogma. Many enzymes such as 
glycosyltransferases, sulfotransferases, sulfatases, and glycanases play important roles 
in the makeup of complicated structures of glycans. These enzymes function together in 
the synthesis of a wide variety of glycan structures. This system enables the 
modification and adoption of the GAG structure in response to environmental changes. 
On the other hand, this non-template biosynthesis system is unable to amplify GAG 
chains unlike DNA and proteins. 
 
Biosynthesis of CS, DS and HS are initiated from the linkage tetrasaccharide, 
GlcA1-3 galactose (Gal)1-3Gal1-4 xylose (Xyl)1- construction (Figure 1-4). At 
first, Xyl-transferation occurs on the seine (Ser) residue on core proteins. Next, two Gal 
residues are successively elongated on the Xyl. Subsequently, GlcA is attached on the 
Gal residue. In CS/DS biosynthesis, GalNAc is attached on the GlcA residue in the 
tetrasaccharides. After that, GalNAc and GlcA are elongated alternatively. During chain 
elongation, some of the hydroxyl groups are sulfated by various sulfotransferases. For 
DS biosynthesis, GlcA residues are epimerized to IdoA and the 2-O group on the IdoA 
residues are sulfated.13 During CS/DS biosynthesis, chondroitin polymerization factors, 
chondroitin synthases, chondtoitin sulfate GalNAc transferases, dermatan sulfate 
epimerases, and various sulfatases work in harmony to construct heterogeneous CS/DS 
chains. For HS/Heparin biosynthesis, the N-acetylglucosamine (GlcNAc) residue is 
attached to the GlcA residue of the tetrasaccharide instead of GalNAc attachment of 
CS/DS biosynthesis. exostosins (Exts), exostosis-like genes (Extls), 
N-deacetylase-N-sulfotransferase (NDST), HS epimerase, and various sulfatases are 
related to HS/Hep biosynthesis. 
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It has been reported that the phosphorylation/dephosphorylation of the Xyl 
and sulfation of the GalNAc residue attached to the linkage tetrasaccharide are strongly 
related to the chain length and amounts of GAG elongated on the tetrasaccharides.13,14 
According to reports, the phosphorylated Xyl residue is required for the construction of 
the linkage tetrasaccharide, while phosphorylation disrupts CS/DS-type chain 
elongation on the tetrasaccharide. Therefore, transient phosphorylation is important for 
the proper construction of GAG chains. In addition, Xyl phosphorylation is related to 
the sulfation efficiency of the GalNAc residue attached to GlcA of the linage 
tetrasaccharide.15 Besides the phosphorylation of Xyl residues, various modifications on 
the tetrasaccharide have also been reported.16–18 However, the regulation mechanisms of 
these modifications and the manner of regulation of the type and sulfation pattern of 
GAG chains are still unknown. 
 
1.2 Saccharide primers 
1.2.1 General information 
Glycans have attracted much interest because of their unique and widely 
varied roles in biological phenomena, so structure–activity relationships of glycans have 
attracted considerable interest as well.19 Structural and functional analyses of glycans 
require large amounts of highly purified samples; however, preparation of these samples 
Figure 1-4 Biosynthesis flow of the linkage tetrasaccharide and GAG repeating disaccharide 
structures. 
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is usually very laborious because of their structural variety. Nevertheless, much effort 
has been made for the purification of the glycans from biological samples or chemical 
synthesis. The structural complexity, which is the branching and modification of the 
glycans, make it difficult to reach this aim. In addition, massive amount of biological 
resources are needed to purify enough amounts of glycans because the amounts of 
glycans in cells are much less than those of proteins. 
 
Saccharide primers, which are artificial initiators of glycan biosynthesis, have 
been used to obtain oligosaccharides synthesized in cells and tissues. The primers have 
amphiphilic structure comprising hydrophobic groups and saccharide residues. The 
primers added to the medium are incorporated into cells and tissues, and transported to 
the endoplasmic reticulum (ER) and the Golgi apparatus where the primers are 
glycosylated through the glycan biosynthetic pathway. Finally the glycosylated primers 
are excreted into the medium. The glycosylation occurs according to the capability of 
glycan biosynthesis by the examined specimen (Figure 1-5). Therefore, saccharide 
primers have been used to obtain a variety of oligosaccharides and to investigate the 
glycan biosynthetic potency of the cells and tissues. 
 
 
The types of the elongated glycans are strongly dependent on the structure of 
saccharide primers. For instance, glycolipid such as gangliosides and lacto/neo-lacto 
glycolipids are elongated on O-alkyl lactosides20, 21 and O-alkyl GlcNAcs22, respectively. 
Figure 1-5 Saccharide primers prime oligosaccharides in a manner of glycan
biosynthesis machinery. 
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For glycan side chains of glycoproteins, GAGs and O-glycans are elongated on 
-xylosides and O-serinyl/threonyl-GlcNAcs, respectively. These saccharide primers 
can be considered as decoys of the biosynthetic initiator of glycoconjugates (Figure 
1-6).  
 
 
1.2.2 -Xylosides 
-Xylosides have been used to obtain GAG-type glycans because of their 
priming abilities for GAG oligosaccharides. For example, Okayama et al. first showed 
that p-nitrophenyl--xylopyranoside (Xyl-pNP) can prime GAG-type oligosaccharide 
when added to chick cartilage cell culture.23 
4-Methylumbelliphenyl--xylopyranoside,24 -estradiol-xylopyranoside,25 naphthol 
xylopyranosides,26–29 C-xylopyranosides,30,31 and “click” xylopyranosides32–35 have also 
been applied for the elongation of GAG oligosaccharides. These -xylosides have been 
used not only as a saccharide primer to obtain the GAG-type oligosaccharides but also 
as a chemical tool to explore the species of glycans potentially produced by cells and 
the colocation of glycosyltransferases on the ER and Golgi apparatus.36 However, the 
major foci in most of these studies have been on the amount, molecular weight, and 
GAG types of primed oligosaccharides, whereas there was not much attention has been 
paid to the intermediates of oligosaccharides primed on the -xylosides. 
Figure 1-6 The structures of saccharide primers. 
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1.3 Aims of this study 
As described above, GAGs play important roles in several intercellular 
biological phenomena, whereas their structure–activity relationships remain unclear. 
The structure of GAG is strongly related to the biosynthetic mechanism and structure of 
the linkage tetrasaccharide. However, a method for evaluating the GAG production 
capability including GAG biosynthesis intermediates has not been developed. 
-xylosides have been used as artificial initiators of GAG chains but the GAG chain 
intermediates elongate on them. Therefore, the aim of this thesis is to discover a 
-xyloside suitable for in-depth analysis of GAG chain intermediates in cells and to 
establish a comparative quantification by the saccharide primer method. The thesis is 
composed of six sections.  
 
The first chapter describes the structures and biological activities, and 
analytical methods are summarized. Additionally, the aim of the study is described. 
 
The second chapter represents a study on the establishment of a synthetic 
scheme for -xylosides that have O-xylosyl amino acid residues using chemoemzymatic 
condensation.  
 
The third chapter represents a study on the priming ability of the four 
-xylosides in NHDF cells. In this chapter, the difference in the priming ability 
including GAG intermediate oligosaccharides is clarified by the optimization of sample 
preparation and LC–MS/MS conditions. 
 
The forth chapter represents the development of a comparative quantification 
method for elongated oligosaccharides using stable-isotope-coded saccharide primer. In 
this chapter, validation of the method was carried out by GAG biosynthesis inhibition 
assay. 
  
The fifth chapter examines the effect of exogenous sulfated GAGs on 
endogenous GAGs production by the comparative quantification method. 
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The sixth chapter summarizes the results and discussions of the thesis. 
Furthermore, the future perspective of the method established in the study is described. 
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Chapter 2  
Chemical Synthesis of Saccharide Primers by Chemoenzymatic 
Condensation 
 
2.1 Introduction 
N-lauroyl-O--D-xylopyranosyl-L-serinamide (Xyl-Ser-C12) showed better 
GAG oligosaccharide priming ability than did p-nitrophenyl xyloside (pNP-Xyl) and 
dodecyl xyloside (Xyl-C12).37 These results imply that the aglycone structure including 
amino acid residues could be strongly affected by the priming ability of the xylosides. 
However, the relationship between the structure of the amino acid in aglycone and the 
priming ability has not been investigated. One reason for this matter is that the synthetic 
scheme of Xyl-Ser-C12 for preparing the derivatives on amino acid structures was not 
appropriate.  
 
In a previous study, Xyl-Ser-C12 was synthesized from the glycosyl donor 
2,3,4-tri-O-acetyl-D-xylopyranosyl trichloroacetimidate (Figure 2-1). This chemical 
synthesis requires multiple steps to control the reaction sites and anomeric selectivity of 
xylose. In addition, de-acetylation process in the final step may cause racemization of 
the Ser residue. These drawbacks make it difficult to change and modify the amino acid 
residue. To overcome these concerns, the synthetic scheme using chemoenzymatic 
condensation was developed.  
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In chemoenzymatic condensation, high selectivity in reaction sites and 
anomeric configuration can be achieved because of the stereoselectivity of glycosidases 
used for synthesis.38 Some studies demonstrated that xylasase, a kind of endo-glycanase, 
can attach xyloside to alchohols.39–42 However, there is no information about the 
chemoenzymatic condensation of xylose with -hydroxyl amino acids. The author’s 
assumption is that endo-xylosidase catalyzes the condensation of xylose and -hydroxyl 
amino acids. Therefore, the chemoenzymatic condensation using endo-xylosidase was 
examined in this study. Endo-1-4 xylanase was chosen as an enzyme, 
xylo-oligosaccharides were chosen as the glycosyl donors, and N-tert-butoxycarbonyl 
serine (Boc-Ser-OH) or N-Boc-threonine (Boc-Thr-OH) was chosen as acceptors.  
 
2.2 Materials and methods 
 Unless otherwise stated, all commercially available reagents and solvent were 
used without purification. All reactions were carried out at room temperature unless 
otherwise noted. All nuclear magnetic resonance (NMR) analyses were performed at 
300 K with a 500 MHz Bruker Advance DRX 500 spectrometer (Bruker BioSpin, 
GmbH). The anomeric configuration of the products was confirmed by 1H-NMR 
spectroscopy. All high resolution mass spectrometory (HRMS) spectra were recorded 
on a Synapt G2-S (Nihon Waters, Tokyo, Japan). The MS was calibrated by NaI before 
the experiments and the resolution was set at high resolution mode. Melting points were 
obtained on a Yanagimoto micro melting point apparatus (Yanagimoto Ltd., Kyoto, 
Figure 2-1 Synthesis of Xyl-Ser-C12.37 
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Japan). Optical rotations were measured on a HORIBA SEPA-200A high sensitive 
polarimeter (Horiba, Tokyo, Japan). 
 
2.2.1 Reverse hydrolysis of xylo-oligosaccharides using xylanases 
Chemoenzymatic condensation is a condensation reaction using a reverse 
reaction of hydrolysis catalyzed by hydrolases. In this study, xylo-oligosaccharides 
were chosen as glycosyl donor, and Boc-Ser was chosen as an acceptor. As enzymes, 
endo-1-4 xylanase (EC 3.2.1.8; Trichoderma longibrachiatum), hemicellulose (EC 
3.2.1.4; Aspergills niger), and cellulose (EC 3.2.1.4; Aspergills niger) (Sigma-Aldrich 
Japan, Osaka, Japan) were screened.  
30 mg of xylo-oligosaccharides and 25 mg of Boc-Ser-OH (Wako Pure 
Chemical Inc. Osaka, Japan) was suspended in 0.5 mL of 10 mM citrate buffer (pH 6.0), 
then, the pH of the suspension was adjusted to 3.0, 4.0, 5.0, and 6.0 by adding 6 M 
KOH. The citrate buffer was added into the suspension to adjust the total volume to 1 
mL. 4 U of one of the enzymes was added into the solution, and then, the mixture 
solutions were mildly stirred to dissolve the enzymes completely. The reaction was 
carried out at 37 oC. 10 L of the reaction solutions were diluted with ultra-purified 
water, heated at 100 oC for 1 min, filtrated by 0.22 m filter, and then, subjected to LC–
MS analysis. 
 
2.2.2 LC–MS analysis 
MS analysis were performed an amaZon speed ETD (iontrap mass 
spectrometer, Bruker Daltonics, Yokohama, Japan) coupled with a Nexera X2 
(Shimadzu, Kyoto, Japan). Instrument control, data acquisition and analysis were 
performed with Hystar (Bruker Daltonics, Yokohama, Japan). 0.1 % formic acid and 
0.1 % formic acid in MeCN were used as mobile phase A and B, respectively. The 
column temperature was set at 40 oC. The data were recorded in negative ion mode from 
100 to 600 m/z. Other ESI conditions were set as follows; Capillary voltage; -3.5 kV, 
dry gas temperature; 250 oC, nebulizer; 3.10 psi, dry gas; 9 L/min, target amount; 70000 
counts/scan, scan mode; ultra scan mode. 
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2.2.3 Synthesis of N -Lauroyl-O--D-xylopyranosyl-L-serinamide (Xyl-Ser-C12) 
and its derivatives 
 
2.2.3.1 N-Boc-O--D-xylopyranosyl-L-serine (5) 
  
 1.8 g of Boc-Ser-OH was dissolved in 2 mL of 50 mM ammonium acetate, 
then, the pH of the solution was adjusted to 5.0 by 6 M KOH. 6.0 g of 
xylo-oligosccharides was added into the solution and stirred vigorously to dissolve the 
xylo-ligosaccharide completely. 320 mg of endo-1-4 xylanase (EC 3.2.1.8; 
Trichoderma longibrachiatum) was suspended in 0.8 mL of 50 mM ammonium acetate, 
and then added into the solution. The solution was gently stirred by pipetting, and kept 
stirred with a magnetic stirrer at 40 oC for 4 days. To quench the reaction, the solution 
was heated in a boiling water bath for 5 min, followed by removal of precipitate by 
filtration. The same volume of brine was added into the solution, and then the products 
was extracted using 40 mL of THF at least 3 times, followed by removal of the solvent 
by vacuum distillation. The crude product was purified by silica gel chromatography 
(2.5 cm i.d. × 20 cm, MeCN/water/formic acid = 97/2/1) to obtain 
N-Boc-O--D-xylopyranosyl-L-serine (5). Yield: 11.1 % (0.327 g). []20 : 31.2 (cell 
length: 100 mm, c = 0.11 g/dL,  = 589 nm). 1H-NMR (D2O):  4.39 (m ,1H, H), 
4.37-4.39 (d, J1, 2 = 8 Hz, 1H, H-1), 4.24 (m, 1H, H-2), 3.93-3.95 (dd, J,  = 5.5 Hz and 
Jgem = 6 Hz, 1H, H-2), 3.92-3.95 (dd, J4, 5 =5.5 Hz and Jgem = 6 Hz, 1H, H-5), 
3.57-3.62 (ddd, J4, 5 = J3, 4 = 4.5, 5, 5.5 Hz, 1H, H-4), 3.41-3.45 (dd, J3, 4 = J2, 3 = 9 Hz, 
1H, H-3), 3.27-3.31 (dd, J4, 5 = 10 Hz and Jgem = 11.5 Hz, 1H, H-5), 3.25-3.29 (dd, J2, 3 
= 8.5 Hz and J1, 2 = 9 Hz, 1H, H-2), 1.436 (s, 9H, (CH3)3). 13C-NMR (D2O);  173.94, 
165.86, 157.67, 103.21 (C-1), 75.55 (C-3), 72.87 (C-2), 69.39 (C-4), 69.18 (Ser-), 
65.09 (C-5), 54.1 (Ser-), 27.61 ((CH3)3). HRMS calcd for C13H23NO9Na [M + H]+: 
360.1265, found: 360.1277.  
 
2.2.3.2 N-Boc-O--D-xylopyranosyl-L-serinamide (6) 
  
 40 mg (0.12 mmol) of compound 5 was dissolved in 2 mL of MeCN and 
stirred well, followed by adding 34 mg (0.18 mmol) of 
1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide Hydrochloride and 27 mg (0.18 
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mmol) of 1-hydroxybenzotriazole ammonium salt (HOBt-NH3). The solution kept 
stirred for 2 h. After removal of MeCN by vacuum distillation, the reaction mixture was 
subjected to silica gel chromatography (2.5 cm i.d. × 20 cm, MeCN/water/formic acid = 
97/3/0.1) to obtain N-Boc-O--D-xylopyranosyl-L-serinamide (6). Yield: 55.7 % (23.2 
mg). 1H-NMR (D2O):  4.40-4.41 (d, J1, 2 = 8 Hz, 1H, H-1), 4.30 (m, 1H, H), 4.14-4.16 
(m, 1H, H-2), 3.95-3.98 (dd, J4, 5 = 5.5, 6 Hz and Jgem = 11.5 Hz, 1H, H-5), 3.88-3.91 
(dd, J,  = 4 Hz and Jgem = 10.5 Hz, 1H, H-1), 3.59-3.64 (ddd, J4, 5 = J3, 4 = 4.5, 5, 5.5 
Hz, 1H, H-4), 3.43-3.47 (dd, J3, 4 = J2, 3 = 9 Hz, 1H, H-3), 3.30-3.40 (dd, J4, 5 = 10.5 Hz 
and Jgem = 11.5 Hz, 1H, H-5), 3.28-3.31 (dd, J1, 2 = 8 Hz and J2, 3 = 9 Hz, 1H, H-2) 1.45 
(s, 9H, (CH3)3). 13C-NMR;  175.09, 171.05, 157.67, 103.04 (C-1), 75.56 (C-3), 72.88 
(C-2), 69.19 (C-4, Ser-), 65.16 (C-5), 54.52 (Ser-), 27.59 ((CH3)3). HRMS: calcd for 
C13H24N2O9Na [M + H]+: 359.1425, found: 359.1440. 
 
2.2.3.3 N -lauroyl-O--D-xylopyranosyl-L-serinamide (1) 
  
 24.5 mg (0.073 mmol) of compound 6 was dissolved in 1 mL of 4 mol/L HCl 
in dioxane and stirred well. After 2 h, the solvent and residual HCl were removed 
completely under reduced pressure. The residue was dissolved in 3 mL of water, and 
then 8.0 L (0.073 mmol) of N-methylmorpholine was added. 22 mg (0.11 mmol) of 
lauric acid dissolved in 2 mL of EtOH was added into the solution, followed by adding 
30 mg (0.11 mmol) of 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium 
chloride (DMT-MM). The solution kept stirred at 45 oC overnight. The next day, 
saturated aqueous NaHCO3 was added and the reaction mixture was extracted with 
AcOEt. The organic phase was removed under reduced pressure and the crude product 
was purified by silica gel column chromatography (1.0 cm i.d. × 20 cm, CHCl3/MeOH 
= 4/1) to obtain Xyl-Ser-C12 (1) as a white solid. Yield: 63.3 % (19.3 mg). Melting 
point: 178.9 oC. []20: 7.2 (c = 0.047), 1H-NMR (CD3COOD):  4.73-4.75 (dd, J,  = 2 
and 5 Hz, 1H, H-), 4.25-4.26 (d, J1, 2 = 7.5 Hz, 1H, H-1), 4.02-4.05 (dd, J,  = 4.5 Hz 
and Jgem = 10.5 Hz, 1H, H-2), 3.84-3.87 (dd, J4,5 = 5.3 Hz and Jgem = 11.5 Hz, 1H, 
H-5), 3.65-3.68 (dd, J,  = 4.5 Hz and Jgem = 10.5 Hz, 1H, H-1), 3.57-3.62 (ddd, J3, 4 = 
5 Hz, J4, 5 = 8.5 Hz, J4, 5 = 10 Hz, 1H, H-4), 3.47-3.50 (dd, J2,3 = J3,4 = 8.8 Hz, 1H, H-3), 
3.27-3.30 (dd, J1, 2 = J2, 3 = 8.5 Hz, 1H, H-2), 3.17-3.22 (dd, J4, 5 = 10 Hz and Jgem = 11.5 
Hz, 1H, H-5), 2.19-2.22 (dd, J = 8.8 Hz, 2H, COCH2), 1.46-1.51 (ddd, J = 7 and 14 
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Hz, 2H, COCH2CH2(CH2)8), 1.16 (m, 16H, CH2(CH2)8CH3), 0.74-0.77 (t, J = 7 Hz, 3H, 
(CH2)8CH3). 13C-NMR (CD3COOD):  174.26 (amide), 103.21 (C-1), 75.42 (C-3), 
72.72 (C-2), 69.02 (C-4, Ser-), 64.47 (C-5), 52.15 (Ser-), 35.25 (COCH2), 25.06 
(COCH2CH2(CH2)8), 22.04, 28.58, 28.74, 28.82, 28.96, 29.01, 31.37 (CH2(CH2)8CH3), 
12.93 ((CH2)8CH3). HRMS: Cald for C20H38N2O7: [M + Na]+, 441,2571. Found: 
441.2575. 
 
2.2.3.4 N-Boc-O--D-xylopyranosyl-L-threonine (7) 
  
 Same method as for compound 5. Purified by silica gel column 
chromatography (2.5 cm i.d. × 20 cm, MeCN/water/formic acid = 96/3/1) to obtain 
compound 7. Yield: 12.5 % (0.180 g). []20: 27.1 (c = 0.1). 1H-NMR (D2O): d 
4.47-4.49 (dd, J,  = 2 Hz and J,  = 6.5 Hz, 1H, H-), 4.39-4.41 (d, J1, 2 = 7.5 Hz, 1H, 
H-1), 4.26 (m, 1H, H-), 3.86-3.99 (dd, J4, 5, = 5.5 Hz and Jgem = 11.5 Hz, 1H, H-5), 
3.56-3.61 (ddd, J4, 5 = J3, 4 = 5, 5.5, 9.5 Hz, 1H, H-4), 3.39-3.43 (dd, J3, 4 = J2, 3 = 9.3 Hz, 
1H, H-3), 3.22-3.27 (dd, J4, 5 = 9 Hz and Jgem = 11.5 Hz, 1H, H-5), 3.20-3.23 (dd, J2, 3 = 
J1, 2 = 8 and 9 Hz, 1H, H-2), 1.443 (s, 9H, (CH3)3), 1.26-1.27 (d, J,  = 6.5 Hz, 3H, H-). 
13C-NMR; d 173.94, 158.18, 100.07 (C-1), 75.64 (C-3), 74.27 (Thr-), 72.77 (C-2), 
69.27 (C-4), 64.85 (C-5), 58.42 (Thr-), 27.61 ((CH3)3) 16.21 (Thr-). HRMS calcd for 
C14H25NO9Na: [M + Na]+, 374.1422. Found: 374.1434.  
 
2.2.3.5 N-Boc-O--D-xylopyranosyl-L-threonamide (8) 
  
 Same method as for compound 6. Purified by silica gel column 
chromatography (2.5 cm i.d. × 20 cm, MeCN/water/formic acid = 97/3/0.1) to obtain 
compound 8. Yield: 75.7 % (39.5 mg). 1H-NMR (D2O):  4.42-4.43 (d, J1, 2 = 8 Hz, 1H, 
H-1), 4.37-4.38 (dd, J,  = 5.3 and 11.8 Hz, 1H, H-), 4.13 (m, 1H, H-), 3.91-3.95 (dd, 
J4, 5 = 5.5 Hz and Jgem = 11.8 Hz, 1H, H-5), 3.58-3.63 (ddd, J4, 5 and J3, 4 = 5, 5.5, 9.5 Hz, 
1H, H-4), 3.42-3.45 (dd, J3, 4 and J2, 3 = 9.3 Hz, 1H, H-3), 3.26-3.30 (dd, J4, 5 = 9 Hz and 
Jgem = 11 Hz, 1H, H-5), 3.23-3.26 (dd, J2, 3 and J1, 2 = 7.5 and 8.5 Hz, 1H, H-2), 1.457 
(s, 9H, (CH3)3), 1.26-1.27 (d, J,  = 6.5 Hz, 3H, H-). 13C-NMR;  175.38, 157.87, 
100.41 (C-1), 75.65 (C-3), 73.66 (Thr-), 72.73 (C-2), 69.29 (C-4), 65.02 (C-5), 58.95 
(Thr-), 27.60 ((CH3)3) 15.83 (Thr-). HRMS calcd for C14H26N2O9Na: [M + Na]+, 
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373.1581. Found: 373.1595. 
 
2.2.3.6 N-lauroyl-O--D-xylopyranosyl-L-threonine (2) 
  
 Same method as for compound 1. Purified by silica gel column 
chromatography (1.0 cm i.d. × 20 cm, CH2Cl2/MeOH = 5/1) to obtain compound 2 as a 
white solid. Yield: 44.3 % (13.9 mg). Melting point: 110.3 oC. []20: 6.8 (c = 0.081). 
1H-NMR (CD3COOD):  4.69 (d, J,  = 4 Hz, 1H, H-), 4.37-4.38 (d, J1, 2 = 7.5 Hz, 1-H, 
H-1), 4.15-4.19 (qd, J,  = 4 Hz and J,  = 6.5 Hz, 1H, H-), 3.84-3.87 (dd, J4, 5 = 5 Hz 
and Jgem = 11.5 Hz, 1H, H-5), 3.57-3.62 (ddd, J4, 5 = 5 and 10 Hz, J3, 4 = 8.5 Hz, 1H, 
H-4), 3.49-3.52 (dd, J3, 4 = J2, 3 = 8.8 Hz, 1H, H-3), 3.25-3.29 (dd, J2, 3 = 9 Hz and J1, 2 = 
7.5 Hz, 1H, H-2), 3.20-3.24 (dd, J4, 5 = 10.5 Hz and Jgem = 11.5 Hz, 1H, H-5), 
2.21-2.24 (dd, J = 7.5 Hz, 2H, COCH2), 1.47-1.51 (ddd, J = 7.5, 7, 6 Hz, 2H, 
CH2(CH2)8), 1.16 (m, 16H, CH2(CH2)8CH3), 1.07-1.08 (d, J,  = 6.5 Hz, 3H, H-), 
0.74-0.77 (t, J = 6.8 Hz, 3H, (CH2)8CH3). 13C-NMR (CD3COOD):  173.82 (amide), 
101.21 (C-1), 75.46 (C-3), 74.01 (Thr-), 72.69 (C-2), 69.08 (C-4), 55.94 (Thr-), 
35.20 (COCH2), 25.15 (CH2(CH2)8), 22.04, 28.58, 28.73, 28.81, 28.96, 29.09, 31.36 
(CH2(CH2)8), 14.73 (Thr-), 12.93 ((CH2)8CH3). HRMS calcd for C21H40N2O7Na: [M + 
Na]+, 455.2728. Found: 455.2738. 
 
2.2.3.7 N-Boc-O--D-xylopyranosyl-L-serinyl glycinamide (9) 
  
 40 mg (0.12 mmol) of compound 5 was dissolved in 2 mL of MeCN. 26 mg 
(0.13 mmol) of glycinamide hydrochrolide, 26 L (0.26 mmol) of N-methylmorpholine, 
and 39 mg (0.18 mmol) of DMT-MM were added into the solution. The mixture was 
stirred 2 h, and then the solvent was removed under reduced pressure. The crude residue 
was purified with silica gel column chromatography (2.5 cm i.d. × 20 cm, 
MeCN/water/formic acid = 90/10/0.1) to obtain compound 9. Yield: 54.8 % (25.0 mg). 
1H-NMR (D2O):  4.39-4.41 (d, J1, 2 = 8 Hz, 1H, H-1), 4.33-4.35 (dd, J,  = 4.5 Hz, 1H, 
Ser-), 4.15-4.18 (dd, J,  = 4.8 Hz and Jgem = 10.3 Hz, 1H, Ser-2), 3.94-3.98 (dd, J4, 5 
= 5.5 and 6.5 Hz, Jgem = 11.3 Hz, 1H, H-5), 3.93 (s, 2H, Gly), 3.90-3.93 (dd, J,  = 3 
and 4.5 Hz, Jgem = 10.3 Hz, 1H, Ser-1), 3.58-3.63 (ddd, J4, 5 = 5.5 and 10.5 Hz, J3, 4 = 9 
Hz, 1H, H-4), 3.42-3.46 (dd, J3, 4 = J2, 3 = 9 and 9.5 Hz, 1H, H-3), 3.28-3.33 (dd, J4, 5 = 
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11 Hz and Jgem = 11.5 Hz, 1H, H-5), 3.24-3.28 (dd, J1, 2 = 8 Hz and J2, 3 = 9.5 Hz, 1H, 
H-2) 1.44 (s, 9H, (CH3)3). 13C-NMR (D2O);  174.17, 173.05, 164.92, 157.66, 102.98 
(C-1), 75.58 (C-3), 72.94 (C-2), 68.95 (Ser-), 65.20 (C-4, C-5), 55.01 (Ser-), 42.21 
(Gly), 27.58 ((CH3)3). HRMS calcd for C15H27N3O9Na: [M + Na]+, 416.1640. Found: 
416.1653. 
 
2.2.3.8 N-lauroyl -O-- D-xylopyranosyl-L-serinyl glycinamide (3) 
  
 23 mg (0.059 mmol) of compound 9 was dissolved in 1 mL of trifluoroacetic 
acid (TFA) and stirred at room temperature, After 15 min, the solvent and TFA was 
removed completely under reduced pressure. The residue was dissolved in 1 mL of 
water, followed by adding 13 mg (0.065 mmol) of lauric acid and 18 mg (0.065 mmol) 
of DMT-MM. The mixture was stirred at 40 oC for 2 h. Saturated aqueous NaHCO3 was 
added and the reaction mixture was extracted with AcOEt. The organic phase was 
removed under reduced pressure and the residue was purified by silica gel column 
chromatography (1.0 cm i.d. × 20 cm, CH2Cl2/MeOH = 4/1). Compound 3 was obtained 
as a white solid. Yield; 93.1 % (26.0 mg). Melting point: 161.4 oC. []20: 14.2 (c = 
0.065). 1H-NMR (CD3COOD):  4.75-4.77 (dd, J,  = 5.5 Hz, 1H, Ser-), 4.26-4.27 (d, 
J1, 2 = 7.5 Hz, 1H, H-1), 4.00-4.03 (dd, J,  = 5 Hz and Jgem = 10.5 Hz, 1H, Ser-1), 
3.94-3.97 (d, Jgem = 17 Hz, 1H, Gly-), 3.87-3.90 (d, Jgem = 17 Hz, 1H, Gly-), 
3.84-3.88 (dd, J4, 5 = 5.3 Hz, Jgem = 12 Hz, 1H, H-5), 3.68-3.71 (dd, J,  = 6 Hz and Jgem 
= 10.5 Hz, 1H, Ser-2), 3.57-3.62 (ddd, J4, 5 = 5.5 Hz, J4, 5 = 10 Hz, J3, 4 = 9 Hz, 1H, 
H-4), 3.46-3.50 (dd J3, 4 = J2, 3 = 9 Hz, 1H, H-3), 3.25-3.28 (dd, J1, 2 = 7.5 Hz and J2, 3 8.5 
Hz, 1H, H-2), 3.18-3.22 (dd, J4, 5 = 10.5 Hz and Jgem = 11.5 Hz, 1H, H-5), 2.18-2.1 (dd, 
J = 7.5 Hz, 2H, COCH2), 1.47-1.50 (m, 2H, CH2(CH2)8), 1.16 (m, 16H, CH2(CH2)8CH3), 
0.74-0.77 (t, J = 6.8 Hz, 3H, (CH2)8CH3). 13C-HMR (CD3COOD):  174.17, 171.30 
(amide), 103, 12 (C-1), 75.48 (C-3), 72.74 (C-2), 69.00 (C-4), 68.85 (Ser-), 64.58 
(C-5), 52.69 (Ser-), 41.78 (Gly), 35.19 (COCH2), 25.06 (CH2(CH2)8), 22.04, 28.58, 
28.73, 28.82, 28.95, 29.09, 29.10, 31.36 ((CH2)8CH3), 12.93 (CH3). HRMS calcd for 
C22H41N3O8Na: [M + Na]+, 498.2786. Found: 498.2801. 
 
2.2.3.9 N-Boc-O--D-xylopyranosyl-L-threonyl glycinamide (10) 
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 Same method as for compound 9. Purified by silica gel chromatography (2.5 
cm i.d. × 20 cm, MeCN/water/formic acid = 90/10/0.1) to obtain compound 10. Yield; 
70.6 % (41.5 mg). 1H-NMR (D2O):  4.41-4.43 (d, J1, 2 = 8 Hz, 1H, H-1), 4.38-4.40 (dd, 
J,  = 3 Hz and J,  = 6 Hz, 1H, Thr-), 4.18-4.19 (m, 1H, Thr-), 3.92 (s, 2H, Gly), 
3.88-3.92 (dd, J4, 5 = 5.5 and 8 Hz, Jgem = 11.8 Hz, 1H, H-5), 3.55-3.60 (ddd, J4, 5 = 5.5 
and 9.8 Hz, J3, 4 = 9.5 Hz, 1H, H-4), 3.41-3.44 (dd, J3, 4 = J2, 3 = 9 and 9.5 Hz, 1H, H-3), 
3.24-3.29 (dd, J4, 5 = 11 Hz and Jgem = 11 Hz, 1H, H-5), 3.19-3.23 (dd, J1, 2 = 8 Hz and 
J2, 3 = 9 Hz, 1H, H-2) 1.45 (s, 9H, (CH3)3), 1.27-1.28 (d, J,  = 6.5 Hz, 3H, Thr-). 
13C-NMR (D2O);  174.24, 173.39, 157.98, 100.25 (C-1), 75.66 (C-3), 73.53 (Thr-). 
72.90 (C-2), 69.28 (C-4), 63.88 (C-5), 59.52 (Thr-), 42.33 (Gly), 27.59 ((CH3)3), 15.73 
(Thr-). HRMS calcd for C16H30N3O9Na: [M + Na]+, 430.1796. Found: 430.1801. 
 
2.2.3.10 N -lauroyl -O--D-xylopyranosyl-L-threonyl glycinamide (4) 
  
 Same method as for compound 3. Purified by silica gel column 
chromatography (1.0 cm i.d. × 20 cm, CH2Cl2/MeOH = 5/1) to obtain compound 4 as a 
white solid. Yield: 57.3 % (21.4 mg). Melting point: 151.7 oC. []20: 16.8 (c = 0.087). 
1H-NMR (CD3COOD): d 4.72-4.73 (d, J,  = 4 Hz, 1H, Thr-), 4.36-4.38 (d, J1, 2 = 7.5 
Hz, 1-H, H-1), 4.16-4.21 (qd, J,  = 4.5 Hz and J,  = 6.5 Hz, 1H, Thr-), 3.93-3.97 (d, 
Jgem = 17.5 Hz, 1H, Gly-), 3.88-3.91 (d, Jgem = 17 Hz, 1H, Gly-), 3.84-3.88 (dd, J4, 5 = 
5 Hz and Jgem = 11.5 Hz, 1H, H-5), 3.58-3.63 (ddd, J4, 5 = 5 and 10 Hz, J3, 4 = 8.5 Hz, 
1H, H-4), 3.48-3.52 (dd, J3, 4 = J2, 3 = 9 Hz, 1H, H-3), 3.24-3.27 (dd, J2, 3 = 9 Hz and J1, 2 
= 7.5 Hz, 1H, H-2), 3.21-3.25 (dd, J4, 5 = 10.5 Hz and Jgem = 11.5 Hz, 1H, H-5), 
2.21-2.24 (dd, J = 7.5 Hz, 2H, COCH2), 1.48-1.51 (ddd, J = 6 and 7 Hz, 2H, CH2(CH2)8), 
1.16 (m, 16H, CH2(CH2)8CH3), 1.07-1.09 (d, J,  = 6.5 Hz, 3H, Thr-), 0.74-0.77 (t, J = 
6.8 Hz, 3H, (CH2)8CH3). 13C-NMR (CD3COOD):  174.31, 170.88 (amide), 101.06 
(C-1), 75.51 (C-3), 74.09 (Thr-), 72.72 (C-2), 69.05 (C-4), 64.65 (C-5), 56.61 (Thr-), 
41.80 (Gly), 35.16 (COCH2), 25.14 (CH2(CH2)8), 22.04, 28.58, 28.72, 28.81, 28.96, 
29.08, 31.36 (CH2(CH2)8), 14.60 (Thr-), 12.93 ((CH2)8CH3). HRMS calcd for 
C23H43N3O8Na: [M + Na]+, 512.2942. Found: 512.2949. 
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2.3 Results and discussion 
2.3.1 Synthetic strategy for Xyl-Ser-C12 and its derivatives 
The proposed synthesis strategy of Xyl-Ser-C12 and its derivatives is shown 
in Figure 2-2. In this scheme, the derivatives could be easily synthesized from these 
amino acid derivatives through Boc-chemistry once N-Boc-O-Xyl-amino acids were 
prepared.  
 
 
2.3.2 Optimization for chemoenzymatic condensation 
Various -xylosides such as alkyl xylosides also have been synthesized by the 
chemoenzymatic condensation; however, to the author’s best knowledge, there are no 
reports about the chemoenzymatic condensation of -hydroxyl amino acids and xylose. 
Therefore, optimization of chemoenzymatic condensation between Ser and Xyl was first 
carried out. 
 
Figure 2-3 shows the extracted ion chromatogram (EIC) (m/z 336.12) 
chromatograms of the reaction solutions with the endo-1-4 xylanase. In the EICs, the 
peaks around 2.5 min were clearly observed. The peak intensity was the highest when 
pH 5.0 buffer was used. The reason for the peak shapes split is the very large amount of 
Boc-Ser-OH was eluted at about 2.5 min. The same peaks were also observed in the 
EICs of the samples reacted with both the hemicellulase and the cellulose; however, the 
peak intensity of the peaks were much lower than those of the endo-1-4 xylanase (data 
not shown). From this result, endo-1-4 xylanase was chosen as the enzyme for the next 
experiment. 
 
Figure 2-2 Chemoenzymatic synthesis of Xyl-Ser-C12 and its derivatives (2-4). 
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Next, the reaction times at various temperatures were investigated. The 
condensations were carried out at 30, 40, and 50 oC in pH 3.0 or 5.0 buffer. An aliquot 
of the reaction solutions was subjected to LC–MS analyses at 0, 3, 6, 24, 48, and 96 h.  
 
As an example, Figure 2-4 shows the LC–MS chromatograms of the reaction 
solution (40 oC, pH 5.0, 96 hours). Boc-Ser-OH, Xyl-Boc-Ser-OH, Hex-Boc-Ser-OH, 
and Xyl2-Boc-Ser-OH were monitored with m/z 204 ([M - H]-), m/z 336 ([M - H]-), m/z 
366 ([M - H]-), and m/z 468 ([M - H]-), respectively. The acceptor and the glycosylated 
products were clearly separated and discriminated by individual EIC channels. Two 
other glycosylated products could be detected. Xyl2-Boc-Ser-OH might be synthesized 
from the condensation of xylobiose and the acceptor. Hex-Boc-Ser-OH might be caused 
by hexoses in the xylo-oligosaccharides. This result implies that the endo-1-4 xylanase 
has both xylanase and hexosidase activities, or that hexosidases are contaminated in the 
endo-1-4 xylanase. 
 
 
 
 
Figure 2-3 EICs of the reaction solutions with the endo-1-4 xylanase (m/z 336.12): (A) pH 3.0,
(B) pH 4.0, (C) pH 5.0, and (D) pH 6.0. LC–MS conditions are described below. A 2.1 mm i.d. × 
50 mm ACQUITY UPLC BEH130 C18, 1.7 >m (Nihon Waters, Tokyo, Japan) was used for 
separation. The column was equilibrated with 5 % B, and the sample was eluted with a 5–15 % B 
linear gradient for 5 min at a flow rate of 0.5 mL/min. 
Chapter 2 
 
28 
 
 
 
 
 
 
 
To investigate the time courses of the reaction, the peak areas of the products 
were plotted on the graphs (Figure 2-5). Figure 2-5A indicates the time course of the 
Xyl-Boc-Ser-OH production at each condition. The production mostly reached plateau 
at 40 and 50 oC in pH 5.0 buffers. Although the production at 30 oC increased according 
to the reaction time, the production was not as much as that at 40 or 50 oC. The 
production was much lower in pH 3.0 buffers. In particular, the production at 50 oC in 
pH 3.0 peaked at 6 h and gradually decreased for 96 h. This result suggests that the 
enzyme was inactivated in 6 h at 50 oC in pH 3.0 buffers. 
 
Figure 2-4 LC-MS chromatograms of the reactant mixture solution (pH 5, 40 oC, 96 h). LC–MS
conditions are described below. A 2.0 mm i.d. × 150 mm UK-C18 (3 8m; Imtakt, Kyoto, Japan) was
used for separation. The column equilibration and sample elution were carried out with a 10%B
isocratic mode. The flow rate was set at 0.4 mL/min. 
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As shown in Figure 2-5C, the production of Xyl2-Boc-Ser-OH was similar to 
that of Xyl-Boc-Ser-OH. In contrast, the production of Hex-Boc-Ser-OH was higher in 
pH 3.0 buffer than in pH 5.0 buffer (Figure 2-5B). This result means that the hexosidase 
activity in endo-1-4 xylanase increases at lower-pH buffer. To maximize the 
Xyl-Boc-Ser-OH production and to minimize the byproducts, the chemoenzymatic 
condensation was determined be carried out at 40 oC in pH 5.0 buffer for 96 h. 
 
To confirm the structure of Xyl-Boc-Ser-OH obtained by the condensation, 
the product was purified by liquid extraction and silica gel chromatography. The peaks 
of the anomeric protons at around 4.37 ppm in the 1H-NMR spectra of the purified 
product are shown. The coupling constants were 7.5 Hz (Figure 2-6). Therefore, it was 
confirmed that the purified products have -anomer configuration. The yields of the 
chemoenzymatic condensations were 11.1 % for Xyl-Boc-Ser-OH. This yield was 
similar to the cases of other chemoenzymatic condensations using glycosidase.38 
 
Figure 2-5 Time courses of the peak areas of the reaction products in several conditions. (A)
Xyl-Boc-Ser-OH, (B) Hex-Boc-Ser-OH, and (C) Xyl2-Boc-Ser-OH. 
Chapter 2 
 
30 
 
 
 
 
Conversion of Xyl-Boc-Ser-OH into the final products was carried out in 
accordance with N-Boc chemistry for peptide synthesis. For conversion of carboxy 
groups into amides, the reactions were carried out using HOBt-NH3 and EDCI.43 
Condensation with lauric acid was carried out with two-step synthesis involving the 
removal of the N-Boc group with acid catalysts (4 M HCl in dioxane) and condensation 
using DMT-MM. The overall yields of the final products were 4.10 % for Xyl-Ser-C12. 
From comparison with the results of the previous report, the number of synthesis steps 
was reduced from 10 to 3. 
 
To expand the structural variety of the -xylosides, the Xyl-Thr-C12, 
Gly-(Xyl)Ser-C12, and Gly-(Xyl)Thr-C12 were synthesized chemoenzymatically. In the 
same manner, N-Boc-O--D-xylopyranosyl-L-threonine (8) was synthesized by the 
chemoenzymatic condensation using N-Boc-Thr-OH as an acceptor, and the yield of the 
condensation was 12.5 %. This result demonstrates the utility of the condensation using 
the xylanase, which can be applied to primary hydroxyl groups but also to secondary 
ones. In the same manner, Xyl-Ser-C12, Xyl-Thr-C12 could be synthesized in 
Figure 2-6 1H NMR spectrum of Xyl-Boc-Ser-OH. The inset is the enlarged around 4.37 ppm. 
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accordance with N-Boc chemistry for peptide synthesis. The total yield of Xyl-Thr-C12 
was 4.91 %, which was comparable to that of Xyl-Ser-C12. For Gly-(Xyl)Ser-C12 and 
Gly-(Xyl)Thr-C12 syntheses, the primary amidation steps were substituted by 
condensation of glycinamide using DMT-MM. The total yields were 5.66 % for 
Gly-(Xyl)Ser-C12 and 5.06 % for Gly-(Xyl)Thr-C12. 
 
Consequently, the synthetic schemes using chemoenzymatic condensation is 
less laborious. Furthermore, N-Boc-Ser and N-Boc-Thr can be useful as a building 
block for xylosylated glycopeptides by N-Boc chemistry, since the result shows that the 
-xyloside group was sufficiently durable for peptide bond construction chemistry. 
Hence, our synthetic strategy for -xyloside is applicable to the synthesis of various 
xylosylated peptides. 
 
2.4. Conclusion 
In this part, the synthetic schemes for Xyl-Ser-C12 and its derivatives were 
established. In particular, the chemoenzymatic condensation using endo-1-4 xylanase 
was useful because it is low-cost, time-effective, and versatile for both primary and 
secondary hydroxyl amino acids. 
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Chapter 3  
Evaluation of GAG Priming Ability of the Saccharide Primers 
3.1 Introduction 
As described in chapter 1, -xylosides have been used as artificial initiators of 
GAG biosynthesis. These -xylosides have been applied to obtain GAG 
oligosaccharides, investigate GAG biosynthetic mechanism, and clarify the localization 
of glycan transferases on ER or Golgi apparatus.36 The types of oligosaccharides 
elongated on -xylosides are deeply related to their aglycone structures, and there are 
many literatures that reported the relationship between the aglycone structure of 
-xylosides and the GAG chain elongated on thereof.24,27,44–49 Most of these studies have 
paid much attention to the amount, molecular weight, and GAG types of primed 
oligosaccharides, whereas not much attention was paid to the intermediates of 
oligosaccharides primed on the -xylosides.  
 
In previous study, it is reported that a novel -xyloside, Xyl-Ser-C12, which 
was designed to resemble the consensus sequence of proteoglycan (PG), showed 
excellent GAG-type oligosaccharides priming ability including various intermediates of 
the linkage tetrasaccharides.37 Form these results, it is possible that the amino acid 
residues in the aglycone affect strongly the priming ability of the -xyloside, and a 
proper -xyloside can be used as a chemical probe for investigation of GAG 
biosynthesis. However, any other investigation about the relationship between the 
structure of the amino acid and the priming ability has not been examined, and 
intermediates of GAG oligosaccharides like phosphorylated ones have not been found 
in the glycosylated products. The reasons given for this include poor recovery of the 
phosphorylated products from the cell culture,50–53 incomparability of the analytical 
apparatus and conditions for the phosphorylated products, and difficulty in 
distinguishing the phosphorylated and sulfated products due to their equivalent nominal 
molecular weights. In other words, it is possible to find the phosphorylated 
oligosaccharides in the glycosylated products when a proper analytical condition is 
applied. 
 
In this chapter, the glycosylated products of Xyl-Ser-C12 and its derivatives 
were investigated to examine their priming abilities. The analytical procedure, from 
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solid phase extraction (SPE) to LC–MS analyses, was optimized to detect the 
phosphorylated products efficiently. The structure of glycosylated products was 
deduced by MS/MS spectra and enzymatic digestion. The priming abilities of the 
-xylosides were compared, and the relationship between the aglycones and priming 
abilities is discussed. 
 
3.2 Materials and methods 
3.2.1 Materials 
 Unless otherwise stated, all commercially available reagents and solvent were 
used without purification. 
 
3.2.2 GAG priming in cells 
 NHDF cells (Kurabo Co., Osaka, Japan) were cultured in Medium 106 
(Thermofisher Scientific, Yokohama, Japan) with NHDF growth supplements, 
gentamicin, and amphotericin B (Kurabo Co., Osaka, Japan) at 37 oC in a humidified 
atmosphere containing 5 % CO2. 
 
 NHDF cells (4 x 105) in a six-well plate were seeded with FibroLife® S2 
Medium Complete kit (Kurabo Co., Osaka, Japan) containing 25 M Xyl-Ser-C12, 
Xyl-Thr-C12, Gly-(Xyl)Ser-C12, or Gly-(Xyl)Thr-C12 for 48 h. 
 
3.2.3 Purification of glycosylated products 
 Purification of glycosylated products was carried out in the previous report, 
with some modification.37 Briefly, the glycosylated products were collected from the 
culture medium using a SPE cartridge. First, 1 mL of 7.5 M Urea was added into the 
culture medium (about 1.5 mL) and stirred well to dissolve precipitate completely in the 
medium, followed by addition of 2.5 mL of 20 mM tetrabutylammonium 
hydrogensulfate (TBA-HSO4). Next, the solution was applied to the cartridge (Strata-X, 
60 mg, 3 mL; Phenomenex, CA) that was conditioned with methanol and equilibrated 
with 10 mM TBA-HSO4. After the cartridge was washed with 2 mL of water and 2 mL 
of 30 % MeOH, the glycosylated products were eluted with 1 mL of 50 % MeOH, 70 % 
of MeOH, and 1 mL of 90 % MeOH. The eluent fractions were collected and the 
solvent was removed under reduced vacuum condition. In order to remove excess 
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amount of TBA, the residues were dissolved with 200 L of water/MeOH/iPrOH (1/1/1, 
v/v) and passed through 200 L of cation exchange resin (Muromachi Chemica, Tokyo, 
Japan) that was washed with MeOH and protonated with 2 % formic acid. After 
removal of the solvent by vacuum distillation, the residues were stored at 20 oC. 
 
3.2.4 LC–ESI–MS of glycolsylated products 
 All solvents and reagents used for LC–MS experiment were LC–MS grade. 
The glycosylated products and the digested samples were subjected to LC–MS analysis. 
MS analysis were performed a Synapt G2-S (quadruple/time-of-flight mass 
spectrometer equipped with ion mobility cell) coupled online by an ACQUITY UPLC 
H-Class Bio (Nihon Waters, Tokyo, Japan). Instrument control, data acquisition and 
analysis were performed with MassLynx software v.4.1. The samples were dissolved in 
water/MeCN (1/3, v/v) and load onto 2.1 mm i.d. × 150 mm ACQUITY UPLC BEH 
Glycan, 1.7 m (Nihon Waters, Tokyo, Japan). Fifty mM ammonium formate buffer 
(pH 7.8) was used as mobile phase A, MeCN as mobile phase B, and 20 mM 
phosphoric acid in 50 % MeCN as mobile phase C. Before every analysis, the 
high-performance liquid chromatography (HPLC) system and the column were flushed 
with mobile phase C at 0.3 mL/min for 3 min so as to avoid undesirable absorption of 
phosphorylated compounds, and then, washed with mobile phase A: mobile phase B = 
50:50 solution at 0.3 mL/min for 2 min. The column was equilibrated with 95 %B then 
the sample was eluted with a 95-50 %B linear gradient for 40 min at a flow rate of 0.4 
mL/min. The column temperature was set at 60 oC. The m/z recorded ranged from 50 to 
1500. The MS calibration was carried out using NaI, and the lock mass spray was setup 
with Leu-enkephalin (m/z 554.2615: [M - H]-). The quadrupole profile was optimized 
not to detect background phosphate ion. The resolution was set to resolution mode 
(approximately 25,000 at m/z 554). Other electrospray ionization (ESI) conditions were 
set as follows; Capillary voltage; 1.5 kV, cone voltage; 30 V, sample offset; 60 V, 
source temperature; 120 oC, desolvation temperature; 500 oC, cone gas; 50 L/h, trap 
collision energy (CE); 2 V.  
 
3.2.5 Enzymatic digestion of the glycosylated products 
 Chondrotinase ABC (C-ABC), chondroitinase ACII (C-ACII), heparitinase I, 
heparitinase II, and heparitinase III were purchased from Seikagaku Corporation (Tokyo, 
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Japan). -D-galactosidase was purchased from Wako Pure Chemical Industries (Osaka, 
Japan). 2-3 sialidase was purchased from Takara Bio (Shiga, Japan). 2,3-6 sialidase 
was purchased from Nakarai Tesque (Kyoto, Japan). To determine the structure of 
glycosylated products elongated on the primers, the glycosylated products were digested 
with GAG lyases and glycosidases. The glycosylated products extracted from the 
medium were dissolved in 100 L of water. For CS/DS digestion, 100 L of 100 mM 
Tris-HCl buffer (pH 8.0) containing 250 mU chondroitinase ABC, 25 mU 
chondroitinase ACII, and 0.005 % bovine serum albumin (BSA) was added. For CS 
digestion, 100 mM sodium acetate buffer (pH 6.0) containing 250 mU chondroitinase 
ACII and 0.005 % BSA was added. For HS digestion, 100 mM sodium acetate, 50 mM 
calcium acetate (pH 7.0) containing 250 mU heparitinase I, II, and III was added. For 
-galactosidase digestion, 100 L of 100 mM phosphate buffer (pH 7.3) containing 
1000 U -D-galactosidase was added. For 2-3 sialidase digestion, 100 mM sodium 
acetate buffer (pH 5.5) and 10 L of 2-3 sialidase were added. For 2,3-6 sialidase 
digestion, 100 mM sodium acetate buffer (pH 5.0) containing 2000 mU 2,3-6 sialidase 
was addwd. The mixture solutions kept 37 oC for 10 min (2-3 sialidase), 2 h (C-ABC, 
ACII), or 17 h (HSases, -galactosidase, 2,3-6 sialidase digestion). All the reactions 
were quenched by heating for 30 sec in boiling water bath. The samples were passed 
through 200 L of cation exchange resin, concentrated, and stored at 20 oC before use. 
 
3.2.6 Statistical analysis 
All values are given as the mean ± standard deviation (SD). Statistical 
analyses were performed using the Student’s t-test available in Microsoft Excel 2010, 
and the level of significance is indicated in figures when more than three independent 
experiments were performed. 
 
3.3 Results and discussion 
3.3.1 Method optimization and structure analysis of phosphorylated products 
 In advance with evaluation of the priming abilities of the -xylosides, the 
protocol to extract the phosphorylated products was optimized.  
 
For the glycosylated products analysis by LC–MS, hydrophilic interaction 
chromatography (HILIC) mode was applied for separation with amide column. The 
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glycosylated products were separated in accordance with the number of saccharide 
residues and sulfate groups. However, the phosphorylated products gave extremely 
broad peaks or were not detected at all. For example, Figure 3-1A shows EICs of the 
phosphorylated products under conventional HILIC conditions. Even though the 
non-phosphorylated products (HexNAc-HexA-Hex-Hex-Xyl-Ser-C12) gave the shape 
peak around 20 min, the all phosphorylated products were not observed. This result is 
probably due to the absorption of the phosphate groups on the stainless steel surface; 
because it is well known that phosphorylated compounds are easily absorbed on surface 
of LC system and it result in poor peaks shapes of the phosphorylated compounds. 
Adding a few amount of phosphoric acid into the mobile phases,54 using ammonium 
bicarbonate buffer in mobile phases,55 and washing LC apparatus with 
ethylenediaminetetraacetic acid (EDTA) solution were taken to solve this problem.56 
Tried these conditions; nevertheless they were not effective to prevent the absorption of 
the phosphorylated products. Finally, the LC system was flushed with phosphoric acid 
solution before every analysis. By flushing LC–MS system with 20 mM phosphoric 
acid in 50 % MeCN, the peak shapes of the phosphorylated products were dramatically 
improved without changing their retention times, peak shapes, and sensitivities of other 
glycosylated products (Figure 3-1B). 
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Next, to maximize recovery of the phosphorylated products, several solid 
phase extraction cartridges and additives were screened. Formic acid (FA), NaCl, or 
TBA-HSO4 were added into the medium, and then, SPE were carried out. The 
recoveries were compared in accordance with the relative intensities of the glycosylated 
products in EICs. A part of the results is shown in Figure 3-2. Among the additives, 
TBA-HSO4 demonstrated the highest recovery for both sulfated and phosphorylated 
products. 
Figure 3-1 EICs of the phosphorylated products. (A) Before phosphoric acid wash. (B) After
phosphoric acid wash. (C) The ion types and m/z values of monitored glycosylated products. S
and P described in the glycosylated products indicate sulfate and phosphate groups, 
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The glycosylated products obtained from the NHDF cell culture were 
prepared and analyzed by the optimized method. Table 3-1 and Table 3-2 show the 
structure, m/z value, ion type, retention time, proportions, and fragment ions of the 
MS/MS spectrum of the detected glycosylated product. The structures of the 
glycosylated products were deduced from the MS/MS spectra and the results of 
enzymatic digestion. In particular, phosphorylated and sulfated products were 
determined by accurate m/z values and observation of m/z 78.9585 ([PO3]) in the 
MS/MS spectra.57 
Twenty-nine glycosylated products were detected from 1.5 mL of the NHDF 
cell culture, of which 11 were considered to be phosphorylated products. 
Figure 3-2 Comparison of the recovery of the phosphorylated and sulfated products obtained 
by SPE. (A) SPE protocols examined in the study. Each additive was used for dilution of the 
medium and the conditioning of SPE cartridge. (B) The tetrasaccharides. (C) The 
pentasaccharides. (D) The heptasaccharides. 
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Table 3-1 Detected glycosylated products elongated on Xyl-Ser-C12. The glycosylated products that 
had identical m/z values but differed in their retention times were distinguished by the numbers after 
underscore. Hex; hexose, HexNAc; N-acetylhexosamine, HexA; hexuronic acid, NeuAc; 
N-acetylneuraminic acid. 
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Table 3-2 MS/MS assignments of the glycosylated products. 
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Figure 3-3 shows the structural analysis of the disaccharide (m/ z 659.2798) as 
an example. In the MS/MS spectrum (Figure 3-3A), [PO3] (m/z 78.9601) was clearly 
observed and hence the disaccharide was considered to be phosphorylated. In addition, 
m/z 497.2288 (Y1), 391.0667 (C2), and 373.0561 (B1) meant glycoside bond cleavage 
ions, suggesting that the phosphorylation occurred on the Xyl. However, in the 
phosphorylated product, peaks at m/z 241.0112 and 259.0222 were also clearly 
observed (shown by arrows in Figure 3-3A). These ions implied the existence of a 
phosphorylated hexose residue in the products, a phenomenon inconsistent with the 
existence of the phosphorylated Xyl residue. To clarify this point, the glycosylated 
products were digested by -galactosidase, followed by the LCMS/MS analysis. 
Figure 3-3B shows the EICs of m/z 659.2798 and 497.2270 (Xyl(P)-Ser-C12) before 
and after -galactosidase digestion, respectively. The peak height at 11.5 min on the 
EIC of m/z 659.2798 (Hex- Xyl(P)-Ser-C12) decreased considerably after digestion, 
whereas that at 5.7 min on the EIC of m/z 497.2270 (Xyl(P)-Ser- C12) largely increased 
after digestion. On the basis of these results, the major component of the 
phosphorylated disaccharide (m/z 659.2798) was deduced to be Gal-Xyl(P)-Ser-C12. 
The fragment ions m/z 241.0112 and 259.0222 in the MS/MS may have been detected 
due to migration of the phosphate group during MS/MS excitation 58 or co-elution of 
Gal(P)-Xyl-Ser-C12.  
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As in the case of the phosphorylated disaccharide, other glycosylated products 
that gave [PO3] ions in their MS/MS spectra were considered to be phosphorylated 
products. These phosphorylated products were deduced to be phosphorylated on the Xyl 
Figure 3-3 Structure analysis of the phosphorylated disaccharide (m/z; 659.2798). (A) MS/MS
spectrum of m/z 659.2798. The y-axis was enlarged 6 times in the m/z range of 50-650. Assignment 
of the fragment ions is described in the figure. Arrows indicate m/z 241.0112 and 259.0222. (B)
Comparison of EIC profiles before and after -galactosidase digestion. The ranges of the vertical 
axis are set equal. 
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residue because Y1 (m/z 497.23) or Y2 (m/z 659.28) ions were observed in their MS/MS 
spectra (Table 3-2). Thus, the phosphorylated products were concluded to be 
intermediates of the linkage tetrasaccharide and GAG oligosaccharides. The major 
reason why the phosphorylated products were not detected in previous studies is 
probably due to the absorption of these products. This result demonstrates the feasibility 
of Xyl-Ser-C12 for use as a chemical probe to investigate the GAG biosynthesis 
mechanism. 
 
Interestingly, not only Xyl-phosphorylated di-, tri-, and tetra- oligosaccharides 
but longer phosphorylated pentasaccharides (m/z 599.7184 and 701.2581) and a 
heptasaccharide (m/z 789.2741) were also detected. The phosphorylated 
pentasaccharide (m/z 599.7184) could be partly digested by heparitinases (Figure 3-4A); 
the major structure of the phosphorylated pentasaccharide was deduced to be 
GlcNAc1-4HexA-Hex-Hex-Xyl(P)-Ser-C12. In contrast, the phosphorylated 
heptasaccharide (m/z 789.2741) could be digested by C-ABC and C-ACII but was not 
digested by heparitinases (Figure 3-4B). Therefore, the structure of the heptasaccharide 
would be GalNAc1-4GlcA1-3GalNAc1-4GlcA-Hex-Hex-Xyl(P)-Ser-C12. 
Izumikawa et al. demonstrated the phosphorylated linkage oligosaccharides to be an 
intermediate of the immature GAG chain resulting from an imbalance of GAG 
xylosylkinase-named family with sequence similarity 20, member B (FAM20B), xylose 
phosphatase, and chondroitin N-acetylgalactosaminyltransferase-1.15 Their results 
indicate that the phosphorylation on Xyl residues may be a discrimination tag to sort the 
linkage oligosaccharides into GAG chain elongation or termination and that these 
enzymes work in harmony to regulate the number, length, and amount of GAG chains 
elongated on PGs. In this study, both phosphorylated and nonphosphorylated 
oligosaccharides that have a linkage tetrasaccharide structure were detected. Thus, the 
ratio of phosphorylated and nonphosphorylated oligosaccharides probably represents 
the capability of GAG biosynthesis of the examined cells. 
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3.3.2 Structural analysis of the glycosylated products by GAG lyase digestion 
 To determine the GAG types of the elongated oligosaccharides, the 
glycosylated products were digested by GAG lyases, followed by the LCMS/MS 
analysis. (Figure 3-5) shows the structural analysis of heptasaccharides (m/z 749.2910). 
In the chromatograms (Figure 3-5A), the untreated sample gave a minor peak at 24.49 
min and a major peak at 25.97 min. After digestion with C-ABC/C-ACII, the major 
peak completely disappeared, whereas the minor peak remained intact. In contrast, the 
minor peak completely disappeared by heparitinase digestion, whereas the entire major 
peak remained. In addition, the cross-ring cleavage ion, 2,5A3 (m/z 480.1401), was 
observed in the MS/MS spectra of m/z 749.2910 at the minor peak (Figure 3-5B), 
indicating the existence of the -HexA1-4HexNAc- structure in the sequence. The 
cross-ring cleavage ion was not observed in the spectra at the major peak (Figure 3-5C). 
Other oligosaccharides composed of repeating disaccharide units were digested by 
C-ABC/C-ACII but not by heparitinase (Figure 3-4B and Figure 3-6). Therefore, the 
heptasaccharide at the minor peak and major peak were considered to be an HS-type 
oligosaccharide and a CS-type oligosaccharide, respectively.  
Figure 3-4 Comparison of EIC profiles before and after GAG lyase digestion. (A) EIC profiles of 
phosphorylated pentasaccharide (HexNAc-HexA-Hex-Hex-Xyl(P)-Ser-C12; m/z 599.7184). (B) EIC 
profiles of phosphorylated heptasaccharide (HexNAc-HexA-HexNAc-HexA-Hex-Hex-Xyl(P)-
Ser-C12; m/z 789.2741). The ranges of the vertical axis are set equal. 
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Figure 3-5 Structural analysis of the heptasaccharides (m/z 749.2910). (A) EIC profiles of the 
heptasaccharides. The ranges of the vertical axis are set equal. (B) The MS/MS spectrum of the 
heptasaccharide at 24.4 min. (C) The MS/MS spectrum of the heptasaccharide at 24.9 min. 
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3.3.3 Structure analysis of sialylated products 
Besides GAG-type oligosaccharides, many sialyloligosaccharides are found in 
the glycosylated products. Among these sialyloligosaccharides, 2-3 sialosides are 
considered to be an unnatural type of oligosaccharides, resulting from misrecognition of 
-xylosides by the glycolipid biosynthesis pathway or an end- capping structure instead 
of phosphorylated Xyl.15,36 To confirm the structure of the sialoside bond of the 
glycosylated products, they were digested by 2-3 sialidase or 2-3,6 sialidase and then 
analyzed by LCMS/MS. The result is shown in Figure 3-7. NeuAc-Hex-Xyl-Ser-C12 
(m/z 870.4089), the most abundant sialyloligosaccharide, completely disappeared by 
digestion with both sialidases (Figure 3-7A). Similarly, NeuAc-Hex-Xyl(P)-Ser- C12 
(m/z 950.3752) and NeuAc-Hex-Hex-Xyl-Ser-C12 (m/z 1032.4617) were digested by 
both sialidases (Figure 3-7B,C), so the sialoside bonds of these products were 
determined to be an 2-3 sialoside bond. In contrast, NeuAc-Hex-Hex-Xyl(P)-Ser- C12 
(m/z 1112.4280) was digested only by 2-3,6 sialidase and not by 2,3 sialidase (Figure 
Figure 3-6 GAG lyase digestion of the nonasaccharide (HexNAc-HexA)3-Hex-Hex-Xyl-Ser-C12. 
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3-7D). This result suggests the structure to be an 2-6 sialoside. 
 
 
NeuAc2-3Hex-Xyl is regarded as an end-capping structure when 
disaccharide structure Hex-Xyl is not phosphorylated properly by FAM20B.59 Therefore, 
the proportions of this sialyloligosaccharide show a tendency of Xyl-Ser-C12 to not be 
incorporated into the GAG biosynthetic pathway. Moreover, NeuAc2-3Hex-Hex-Xyl 
is also considered to be an end-capping structure because the C3 position of the 
nonreducing end, Hex, where GlcA should be attached, was occupied by sialic acid. In 
contrast, some sialyloligosaccharides that were phosphorylated on the Xyl residue were 
Figure 3-7 Comparison of EIC profiles before and after sialidase digestion. (A) EIC profiles of 
NeuAc-Hex-Xyl-Ser-C12; m/z 870.4089). (B) EIC profiles of NeuAc-Hex-Xyl(P)-Ser-C12; m/z
950.3752). (C) EIC profiles of NeuAc-Hex-Hex-Xyl-Ser-C12; m/z 1032.4617). (D) EIC profiles of 
NeuAc-Hex-Hex-Xyl(P)-Ser-C12; m/z 1112.4280). The ranges of the vertical axis are set equal. 
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also detected. This result did not agree with the GAG biosynthesis mechanism 
controlled by FAM20B, suggesting that the sialylation might occur by a different 
biosynthesis mechanism. 
In addition, the sialyltetrasaccharide (NeuAc2-6Hex-Hex-Xyl(P)-Ser-C12) 
had another sialoside bond structure. Recently, sialylation on the Gal residue of the 
linkage tetrasaccharide in the human inter--trypsin inhibitor was reported.16,60 This 
implies that 2-6 sialoside might be added on the Gal residues of the linkage 
tetrasaccharide during GAG biosynthesis. Therefore, 
NeuAc2-6-Hex-Hex-Xyl(P)-Ser-C12 might be a novel intermediate structure of GAG 
biosynthesis. On the basis of these results, sialylation on the -xyloside might be a key 
factor to understanding the GAG biosynthetic mechanism. In this regard, Xyl-Ser-C12 
could be a powerful tool to investigate the GAG biosynthetic mechanism because 
Xyl-Ser-C12 is able to prime phosphorylated, GAG-type, and sialyloligosaccharides all 
at the same time. 
 
 
3.3.4 Quantitative analysis of the glycosylated products obtained from the 
-xylosides 
 
To confirm the relationship between the structure and priming ability of each 
-xyloside, the proportions of the glycosylated products were calculated and compared. 
In the same manner as that for the glycosylated products of Xyl-Ser-C12, those of other 
-xylosides were deduced by LCMS/MS and enzymatic digestion. The proportions 
were calculated from the peak areas of the glycosylated products. The results are shown 
in Table 3-3, Table 3-4, Table 3-5, Table 3-6, Table 3-7, Table 3-8, Table 3-9, and 
Figure 3-8.  
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Table 3-3 Detected glycosylated products elongated on Xyl-Thr-C12. The glycosylated products that 
had identical m/z values but differed in their retention times were distinguished by the numbers after 
underscore. 
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Table 3-4 MS/MS assignments of the glycosylated products elongated on Xyl-Thr-C12. 
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Table 3-5Detected glycosylated products elongated on Gly-(Xyl)Ser-C12. The glycosylated 
products that had identical m/z values but differed in their retention times were distinguished by the 
numbers after underscore. 
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a The product digested by heparitinases. 
b The product digested by C-ABC. 
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Table 3-6 MS/MS assignments of the glycosylated products elongated on Gly-(Xyl)Ser-C12. 
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Table 3-7 Detected glycosylated products elongated on Gly-(Xyl)Thr-C12. The glycosylated 
products that had identical m/z values but differed in their retention times were distinguished by the 
numbers after underscore. 
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Table 3-8 MS/MS assignments of the glycosylated products elongated on Gly-(Xyl)Thr-C12 
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Table 3-9 Proportions of glycosylated products obtained from NHDF cells. The average values were 
obtained from three individual experiments. S. D. means standards deviations.  
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Among the -xylosides, Xyl-Ser-C12 primed the maximum amount of 
glycosylated products (Table 3-9). Among the glycosylated products of Xyl- Ser-C12, 
the most abundant product was a phosphorylated pentasaccharide 
(HexNAc-HexA-Hex-Hex-Xyl(P)-Ser-C12) (20.91 %). The sum of the proportion of 
phosphorylated products obtained from Xyl-Ser-C12 is about 50 %. These 
phosphorylated products have not been detected in previous studies (Figure 3-8).37,61 
These results suggest that Xyl-Ser-C12 works as an appropriate substrate for Xyl 
phosphorylation, and the phosphorylated products were easily excreted into the medium. 
Furthermore, the sum of the proportion of GAG-type oligosaccharides, which were 
composed of the linkage tetrasaccharides, was about 40 % (Figure 3-8B). Taking into 
consideration the fact that the phosphorylated products were the intermediates of GAG 
biosynthesis, a large part of Xyl-Ser- C12 was incorporated into the GAG biosynthesis 
pathway. The total proportion of the sialyloligosaccharides was approximately 17 %. 
Therefore, some part of Xyl-Ser-C12 taken by NHDF cells may be recognized by 
sialyltransferases. 
 
Similar to Xyl-Ser-C12, Gly-(Xyl)Ser-C12 also initiated mainly GAG-type 
Figure 3-8 Total proportion of (A) phosphorylated, (B) GAG type, and (C) sialyloligosaccharides
elongated on the -xylosides. Double asterisk (**) denotes p < 0.01 in Student’s t-test. 
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oligosaccharides. The most abundant product was the phosphorylated pentasaccharide 
(HexNAc-HexA-Hex-Hex-Xyl(P)-GlySer-C12) (36.75 %). In comparison with 
Xyl-Ser-C12, phosphorylated products and GAG-type oligosaccharides were slightly 
but not significantly increased (Figure 3-8A, B). In addition, it is notable that the 
amount of sialyloligosaccharides elongated on Gly-(Xyl)Ser-C12 was significantly 
lower than that on Xyl-Ser-C12 (Figure 3-8C). These results suggest that the Gly 
residue flanked by the Ser residue in Gly-(Xyl)Ser-C12 affects the efficiency of Xyl 
phosphorylation and sialylation. Gly-(Xyl)Ser-C12 would be a better primer to 
construct GAG-like oligosaccharide libraries because 2-3 sialylated oligosaccharides, 
which are the end-capping structure, were undesirable to obtain phosphorylated and 
GAG-type oligosaccharides. 
 
Xyl-Thr-C12 and Gly-(Xyl)Ser-C12 gave fewer species of elongated 
oligosaccharides than either Xyl-Ser-C12 or Gly-(Xyl)Ser-C12 (Table 3-9). They 
initiated large amounts of sialyloligosaccharides, such as NeuAc2-3Hex-Xyl-R, and 
small amounts of both phosphorylated and GAG-type oligosaccharides (Figure 3-8A
C). Therefore, these -xylosides, which are composed of a Xyl-Thr residue, are unlikely 
to work well for Xyl phosphorylation. 
 
 
3.4 Conclusion 
In this study, we established an analytical method for phosphorylated 
oligosaccharides elongated on the saccharide primers, by which a wide variety of 
oligosaccharides could be observed using LCMS/MS. Most of these oligosaccharides 
seemed to be synthesized in accordance with the GAG biosynthetic pathway (Figure 
3-9). These results indicate that the -xylosides prime phosphorylated GAG-type 
oligosaccharides in living cells. In addition, the comparison of the relative amounts of 
these oligosaccharides revealed that the proportions of phosphorylated oligosaccharides 
and sialylated oligosaccharides were completely different between the primers. To our 
best knowledge, this is the first report to demonstrate that the amino acid residues 
around the Xyl attachment position strongly affect phosphorylation efficiency. Taking 
into consideration the GAG biosynthetic pathway, our results suggest that both 
phosphorylation and 2-3 sialylation are related to the GAG priming ability of the 
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primers. Notably, these oligosaccharides included phosphorylated 2-6 
sialyloligosaccharides, implying that both sialylation and Xyl phosphorylation might 
orchestrate the GAG biosynthesis mechanism. However, the function of the 2-6 
sialylation in the GAG biosynthesis mechanism remains to be discussed further, thus 
in-depth analysis of the phosphorylated sialyloligosaccharides is needed. 
 
 
-Xylosides with amino acid residues in their aglycone were synthesized by 
chemoenzymatic synthesis to examine the effect of the aglycone structure on the 
Figure 3-9 Speculated biosynthesis pathways of glycosylated products elongated on saccharide
primer. The biosynthesis is initiated with galactosylation on the Xyl. The disaccharide is 
phosphorylated for GAG-type oligosaccharide biosynthesis. The phosphorylated disaccharide is 
used as an intermediate of GAG biosynthetic pathway. Dephosphorylation can be occurred during 
both GlcA addition on the phosphorylated trisaccharide and GalNAc addition on the phosphorylated 
tetrasaccharide. The phosphorylated trisaccharide can be modified by 2-6 linked NeuAc for sialyl
GAG synthesis. Without the Xyl phosphorylation, the disaccharide can be capped by 2-3 linked 
NeuAc. Gal, HexA, and HexNAc residues can be sulfated during the biosynthesis. 
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priming ability. The amino acid residues strongly affect the structure of 
oligosaccharides, especially phosphorylated oligosaccharides. The -xylosides 
synthesized in this study demonstrated high priming ability for a wide variety of 
oligosaccharides, providing a chemical tool not only to obtain GAG-type 
oligosaccharides but also to investigate the GAG biosynthesis mechanism. This study is 
an important step in the development of a new methodology using -xylosides to clarify 
the GAG biosynthesis mechanism and for the comparison of glycosaminoglycomics 
between different cells and tissues. 
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Chapter 4  
Method Development for Comparative Quantification for Priming 
Oligosaccharides Using a Stable Isotope Labeled Saccharide Primer. 
 
4.1 Introduction 
There are several reports of the use of saccharide primers for comparative 
glycomics studies.30,61 Comparison of the glycosylated products has been carried out by 
several analytical techniques such as high-performance thin-layer chromatography,20,62 
HPLC,63 and LC–MS.37,61,64 However, accurate comparative quantification remains 
challenging because experimental processes such as solid phase extraction, LC 
separation and MS detection may cause experimental errors. Therefore, a more accurate 
comparative quantification method for glycosylated products is required. 
 
In the MS field, the isotope-labeling strategy is a promising approach for 
relative quantification and is widely used in omics studies.65–67 There are two 
approaches for stable isotope labeling: metabolic labeling and chemical modification. 
Specifically, metabolic labeling approaches like stable isotope labeling using amino 
acids in cell culture (SILAC) in proteomics are highly reliable for comparative 
proteomics because these methods can circumvent experimental bias caused by the 
chemical modification process.68–71 In regards to glycomics research, several 
isotope-labeling methods have been developed.72 For example, reductive amination,73–75 
reducing end modification,76 and permethylation77 have been used for the chemical 
labeling approach. On the other hand, there are a few studies focusing on the metabolic 
labeling approach in the glycomics field. For instance, isotopic detection of 
aminosugars with glutamine (IDAWG) is a metabolic labeling technique using 
amide-15N Gln to introduce 15N into hexosamines.78 In this approach, “heavy” glycans 
are increased 1 Da in their molecular weight per amino sugar residue. However, this 
increase is not sufficient to discriminate “light” and “heavy” products because the MS 
peaks of “light” glycans could overlap the peaks of “heavy” glycans. This overlap might 
result in inaccurate quantification. Hence, a more accurate and reliable approach is 
required to compare the amounts of glycosylated products elongated on saccharide 
primers. 
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Here, we established a relative quantification method for comparative 
glycomics research using an isotope-labeled saccharide primer. In this method, a pair of 
deuterium-labeled and non-labeled saccharide primers is used for comparison of GAG 
biosynthesis in cells. In order to demonstrate the feasibility of this method for 
comparative glycomics study, effects of known GAG biosynthesis inhibitors for living 
cells were confirmed using the method. 
 
4.2 Materials and methods 
4.2.1 Materials 
NHDF cells were purchased from Kurabo Industries Ltd. (Osaka, Japan). 
DMEM GlutaMax, and DMEM without phenol red were purchased from Thermo Fisher 
Scientific (Yokohama, Japan). Lauric acid-d5 was purchased from Sigma-Aldrich Japan 
(Tokyo, Japan). All other chemical reagents were purchased from Sigma-Aldrich Japan 
(Tokyo, Japan), Wako Pure Chemical Industries Ltd. (Osaka, Japan), and Tokyo 
Chemical Industries Co., Ltd. (Tokyo, Japan). Unless otherwise stated, reagents and 
solvents were used without purification. 
 
4.2.2 Chemical synthesis of Gly-(Xyl)Ser-C12-d5 (heavy primer) 
23 mg (0.059 mmol) of N-Boc-O--D-xylopyranosyl-L-serinyl glycinamide 
was dissolved in 1 mL of TFA and stirred at room temperature. After 15 min, TFA was 
removed completely under reduced pressure. The residue was dissolved in 1 mL of 
water, followed by the addition of 13 mg (0.065 mmol) of lauric acid-d5 and 18 mg 
(0.065 mmol) of DMT-MM. The mixture was stirred at 40 °C for 2 h. Saturated 
aqueous sodium bicarbonate was added and the reaction mixture was extracted with 
ethyl acetate. The organic phase was removed under reduced pressure and the residue 
was purified by silica gel column chromatography (1.0 cm i.d. × 20 cm, 
chloroform/methanol = 4/1). Gly-(Xyl)Ser-C12-d5 was obtained as a white solid. Yield: 
93.1 % (26.0 mg). Melting point: 161.4 °C. []20: -14.2 (c = 0.065). 1H-NMR 
(CD3COOD): d 4.75-4.77 (dd, J,  = 5.5 Hz, 1H, H-), 4.26-4.27 (d, J1, 2 = 7.5 Hz, 1H, 
H-1), 4.00-4.03 (dd, J,  = 5 Hz and Jgem 10.5 Hz, 1H, H-1), 3.94-3.97 (d, Jgem = 17 Hz, 
1H, CH2(Gly)), 3.87-3.90 (d, Jgem = 17 Hz, 1H, CH2(Gly)), 3.84-3.88 (dd, J4, 5 = 5.3 
Hz and Jgem = 12 Hz, 1H, H-5), 3.68-3.71 (dd, J,  = 6 Hz and Jgem = 10.5 Hz, 1H, 
H-2), 3.57-3.62 (ddd, J4, 5 = 5.5 Hz, J4, 5 = 10 Hz, J3, 4 = 9 Hz, 1H, H-4), 3.46-3.50 (dd 
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J3, 4 = J2, 3 = 9 Hz, 1H, H-3), 3.25-3.28 (dd, J1, 2 = 7.5 Hz and J2, 3 = 8.5 Hz, 1H, H-2), 
3.18-3.22 (dd, J4, 5 = 10.5 Hz and Jgem = 11.5 Hz, 1H, H-5), 2.18-2.1 (dd, J = 7.5 Hz, 
2H, COCH2), 1.47-1.50 (m, 2H, CH2(CH2)7CD2CD3), 1.12-1.15 (m, 14H, 
CH2(CH2)7CD2CD3). 13C-NMR (CD3COOD): 18.50, 18.66, 18.82, 18.87, 18.97, 19.03, 
19.14, 25.05, 28.58, 28.73, 28.79, 28.95, 29.10, 31.08, 35.19, 41.78, 52.69, 64.58, 68.85, 
69.00, 72.74, 75.48, 103.12, 171.31, 174.17, 175.69. HRMS calculated for 
C22H41N3O8Na: [M + Na]+, 503.3100. Found: 503.3106. 
 
4.2.3 Priming of elongated-oligosaccharides on the saccharide primers 
The primers were purified by reverse phase HPLC in advance. NHDF cells 
were cultured and expanded in DMEM GlutaMax medium with 10 % fetal bovine 
serum and 1% penicillin-streptomycin solution in a humidified atmosphere containing 
5 % CO2. 
To confirm differences in the priming abilities, NHDF cells (4 x 106) were 
seeded onto a 15 cm dish and cultured for 18 h to 80 % confluence. After washing with 
PBS, the cells were incubated with 10 mL of phenol red-free DMEM containing 25 M 
of the light or heavy primer for 3 days. For the linearity test, NHDF cells (4 x 105) were 
seeded onto the wells of a six-well plate and cultured for 18 h to 80 % confluence. After 
washing with phosphate-buffered saline (PBS), the cells were incubated with 1 mL of 
phenol red-free DMEM containing 25 M of the light primer for 3 days. When 
examining GAG biosynthesis inhibition, phenol red-free DMEM containing 10 or 100 
M of each inhibitor was used. After 3 days incubation, the media and cells were 
harvested. When the media were transferred to tubes, the wells and plates were washed 
with 0.5 mL and 3 mL of PBS, respectively, and the PBS wash solutions were 
combined with the respective media. The cells were removed by centrifugation, and 
then each medium was transferred to a 5 mL tube. The medium containing the heavy 
primer was collected in the same manner and transferred to a 15 mL tube. The collected 
medium was store at 80 °C until use. 
 
4.2.4 Sample preparation 
In the experiment, the elongated oligosaccharides on the heavy primer were 
used internal standards. A 0.75-mL aliquot of the “heavy” medium was added into the 
same volume of the “light” medium collected from a well and mixed. The glycosylated 
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products in the mixed medium were extracted using a solid-phase extraction cartridge. 
A 45-L aliquot of 0.5 mol/L dibutylammonium acetate (DBAA) solution was added 
into 1.5 mL of the culture medium and stirred well. The mixed solution was applied to a 
Strata-X cartridge (60 mg, 3 mL, Phenomenex, Torrance, CA), which had been washed 
with methanol and equilibrated with 20 mM DBAA in advance. After the cartridge was 
washed with 2 mL of water and then 2 mL of 30 % MeOH, the glycosylated products 
were eluted with 0.5 mL of 90 % MeOH twice. The eluted fractions were subjected to 
centrifugal evaporation to remove the solvent. The residues were dissolved in 30 L of 
MeCN/MeOH/5 mM (NH4)2HPO4 (15/3/2) and filtrated using 0.22 m filters. The 
filtrated solutions were subjected to LC–MS/MS analysis. 
 
4.2.5 LC–MS/MS analysis 
LC–MS/MS analysis was performed using a Synapt G2-S coupled to an 
Acquity UPLC H-Class Bio (Nihon Waters, Tokyo, Japan). The glycosylated products 
were separated by Acquity UPLC BEH Glycan (2.1 mm x 150 mm, 1.7 m) at 60°C. A 
50-mM concentration of ammonium formate buffer (pH 7.8) was used as solvent A and 
pure acetonitrile was used as solvent B. The flow rate was set at 0.2 mL/min. The 
glycosylated products were eluted in a linear gradient (95 % B to 60 % B in 40 min). 
The data were recorded in MS mode for quantification and MS/MS mode for structure 
analysis. The polarity was in negative ion mode. For all analyses, the resolution was set 
to sensitivity mode (resolution approximately 10,000 at m/z 554). MS recording range 
was 400-1500 in MS mode and 50-1500 in MS/MS mode. Other MS parameters are 
shown below. Capillary voltage: 0.3 kV, cone voltage: 20 V, source offset: 20 V, 
source temperature: 350 °C, desolvation gas flow: 1200 L/h, desolvation gas 
temperature: 600 °C, nebulizer gas: 6.0 L/min, trap CE: 20 V at low CE and 70 V at 
high CE, transfer CE: 2 V. All LC–MS data were analyzed using MassLynx software 
ver. 4.1 (Waters). 
 
4.2.6 Data analysis for comparative quantification 
The light/heavy rate of elongated oligosaccharides was calculated based on 
EIC chromatograms generated by MassLynx software ver. 4.1. The relative peak area 
(Rpi) of a glycosylated product was calculated using the following equation. 
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  


 
 
Where Lpi and Hpi are the peak area of a glycosylated product elongated on 
the light primer and that of the heavy primer, respectively. To compare the effects of 
GAG biosynthesis inhibitors, the relative amount of a glycosylated product obtained 
from each GAG inhibitor-added medium was calculated by dividing the Rpi of each 
inhibitor by the average of Rpi obtained from the control media. Statistical analyses 
were performed with a Student’s t test using Microsoft Excel 2010. 
 
4.2.7 Structural analysis of the glycosylated products 
Determination of compositions of the glycosylated products and assignment 
of fragmentation ions in MS/MS spectra was accomplished using GlycoWorkbench 
version 2.179 and ChemDraw Std 12.0. Briefly, saccharide composition of the 
glycosylated products was determined according to the m/z values of MS spectra. 
Assignments of fragment ions in MS/MS spectra were carried out according to the 
nomenclature introduced by Domon and Costello.80 The confirmation of the 
glycosylated products elongated on the primers was based on diagnostic fragment ions 
related to the aglycone structure such as Z0 and Z0 H2O. Glycan sequences were 
deduced by the fragment ions caused by the glycoside bond cleavage. Discrimination of 
sulfated or phosphorylated products was carried out relying on the observation of 
[HSO4]- ion and [PO3]- ion in MS/MS spectra. The diagnostic fragment ions and neutral 
losses are shown below. 
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Table 4-1 Diagnostic fragment ions observed in the MS/MS spectra for the glycosylated products 
elongated on the light primer. 
Structure Fragment ions Ionic formula m/z 
GlySerC12 Z0 C18H34N3O2 324.27 
 Z0  H2O C18H32N3O 308.27 
 - C16H29N2O2 281.22 
 - C14H27N2O2 255.21 
 - C14H24NO2 238.18 
    
Hex [Hex  H] C6H11O6 179.06 
 [Hex  H2O  H] C6H9O5 161.05 
    
HexNAc [HexNAc  H] C8H14NO6 220.08 
 [HexNAc  H2O  H] C8H12NO5 202.07 
    
HexA [HexA  H] C6H9O7 193.04 
 [HexA  H2O  H] C6H7O6 175.02 
 [C5H5O3] C5H5O3 113.02 
    
NeuAc [NeuAc  H2O  H] C11H16NO8 290.09 
 [C3H3O3] C3H3O3 87.01 
    
    
Phosphate [PO3] PO3 78.96 
 [H2PO4] H2PO4 96.97 
    
Sulfate [HSO4] HSO4 96.96 
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Table 4-2 Diagnostic neutral losses observed in the MS/MS spectra for the glycosylated products 
elongated on the light primer. 
Structure Neutral losses Compositional formula m/z 
GlySerC12 GlySerC12  H2O C18H35N3O2 325.27 
    
    
Xyl Xyl  H2O C5H8O4 132.04 
 Xyl C5H10O5 150.05 
    
Hex Hex  H2O C6H10O5 180.06 
 Hex C6H12O6 162.05 
    
HexA HexA  H2O C6H8O6 176.03 
 HexA C6H10O7 194.04 
    
HexNAc HexNAc  H2O C8H13NO5 203.08 
 HexNAc C8H15NO6 221.09 
    
NeuAc NeuAc  H2O C11H17NO8 291.10 
    
Phosphate HPO3 HPO3 79.97 
    
Sulfate SO3 SO3 79.96 
    
Carboxylate CO2 CO2 43.99 
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4.3 Results and discussion 
4.3.1 Strategy for comparative quantification of the elongated oligosaccharides 
 Figure 4-1 illustrates the strategy used in the comparative quantification 
experiment. The pair of primers can be synthesized from 
N-Boc-O--D-xylopyranosyl-L-serinyl glycinamide by a one-pot reaction (Figure 4-1A, 
B). The primers were added into the cell culture media individually and incubated to 
obtain each glycosylated product separately. After glycosylation, the heavy medium 
was added into the light medium, the mixtures are extracted by solid phase extraction 
and then subjected to LC–MS analysis (Figure 4-1C). This procedure can offset 
experimental errors related to sample preparation and LC–MS detection. In addition, the 
glycosylated products gave doublet peaks in the MS spectra. In accordance with the MS 
signal intensities of heavy products and light products, relative amounts of the 
glycosylated products were calculated. Moreover, this feature helps to discriminate the 
peaks of glycosylated products from background signals related to medium 
components. 
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Figure 4-1 Comparative quantification strategy using isotope-labeled saccharide primers. (A) The
saccharide primers used in this study. The heavy primer is deuterated in the fatty chain. (B)
Synthetic scheme of the primers. Conditions and reagents; (a) TFA, r.t., 15 min. (b) Lauric acid,
DMT-MM, EtOH/H2O, 40 °C, 2 h. (C) Schematic flow chart for the comparative quantification. 
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4.3.2 Structure analysis of elongated oligosaccharides by LC–MS/MS 
 Analysis of the sample extracted from the light medium revealed 32 
glycosylated products detected by LC–MS. In chapter 3, the glycosylated products 
elongated on Gly-(Xyl)Ser-C12 were identified using MS/MS and enzymatic digestion. 
In reference to the previous result, the structures of the glycosylated products detected 
in this study could be deduced with the MS/MS spectra (Table 4-3).  
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Table 4-3 Theoretical m/z values, experimental m/z values, and errors of glycosylated products 
elongated on the primers. The glycosylated products that had identical m/z values but differed in 
their retention times were distinguished by the numbers after underscore. 
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a The product digested by heparitinases. 
b The product digested by C-ABC. 
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Some glycosylated products were successfully analyzed using MS/MS and 
enzymatic digestion; however, some structural features such as glycoside bond linkages 
or sulfation position have not been determined. For example, four peaks were detected 
in sulfated pentasaccharides (S+HexNAc-HexA-Hex-Hex-Xyl-R), and their MS/MS 
spectra implied that their sulfation positions were different (Figure 4-2, Figure 4-3, 
Figure 4-4, and Figure 4-5). To understand the GAG biosynthesis mechanism of 
individual cells and tissues, structural analysis including these structural features of 
glycosylated products are needed. 
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Figure 4-2 MS/MS spectrum of S + HexNAc-HexA-Hex-Hex-Xyl-GlySerC12_1.  
Figure 4-3 MS/MS spectrum of S + HexNAc-HexA-Hex-Hex-Xyl-GlySerC12_2. 
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4.3.3 Method verification 
Although deuterium labeling is the first choice for stable isotope labeling in 
LC–MS quantification, there are some drawbacks using deuterium-labeled compounds 
as internal standards. Foremost, deuterium-labeled compounds could be separated from 
the originals in LC analysis.81 This separation might cause miss-assignment of the pairs 
and introduce bias in the quantification result. The composition of the mobile phase and 
Figure 4-5 MS/MS spectrum of S + HexNAc-HexA-Hex-Hex-Xyl-GlySerC12_3. 
Figure 4-4 MS/MS spectrum of S + HexNAc-HexA-Hex-Hex-Xyl-GlySerC12_4. 
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the conditions of the MS equipment could affect retention times, and this instability 
may affect the ionization efficiencies of the examined compounds. Hence, we first 
confirmed the retention times of both glycosylated products elongated on light and 
heavy primers. 
 
 Table 4-4 shows retention times and differences in retention times (RT) of 
the glycosylated products obtained from the light and heavy primers. Surprisingly, most 
of the glycosylated product pairs showed the same retention times and RTs were 
obviously small; the largest RT was 0.03 ± 0.03 min. In addition, to investigate 
retention behavior in detail, the peak shapes of the pairs of glycosylated products were 
compared. Figure 4-6 illustrates example pairs of EIC chromatograms elongated on the 
primers. The retention times and peak shapes of each pair appeared identical. These 
results mean that the deuterium group in the heavy primer does not affect the retention 
time of HILIC separation. This might be because the hydrophilic moiety, the saccharide 
chain in this case, is the main contributor to the interaction with the HILIC stationary 
phase, whereas the hydrophobic moiety of the primers does not contribute to the 
interaction. This information may expand the utility of deuterium-labeled compounds as 
stable isotope-labeled standards by coupling with HILIC separation. In light of this 
result, we proposed the use of the glycosylated products of the heavy primer as internal 
standards of those of the light primer. 
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Table 4-4 Retention times and RT of the glycosylated products. RT values represent the means ± 
standard deviations (S. D.) of three independent experiments. 
Glycosylated products 
Retention times 
RT 
Light Heavy 

 8.45 8.45 0.00 ± 0.00 


 12.31 12.32 0.00  0.01 

 13.87 13.87 0.01  0.01 

	
 13.89 13.89 0.00  0.00 


 15.93 15.94 0.01  0.01 


 16.64 16.65 0.01  0.01 

	

 16.27 16.27 0.00  0.01 

	
 17.31 17.32 0.00  0.01 

	

	
 19.22 19.23 0.01  0.01 



 17.84 17.84 0.00  0.00 



 17.97 17.97 0.00  0.00 

	


 18.97 18.97 0.00  0.00 



 20.71 20.71 0.00  0.01 

	

 19.11 19.11 0.00  0.01 

	


 18.63 18.63 0.00  0.00 

	


 19.04 19.02 0.03  0.03 

	


 19.14 19.14 0.00  0.01 

	


 19.43 19.43 0.00  0.00 

	
	

 21.23 21.23 0.00  0.01 

	


 21.36 21.36 0.00  0.00 


	


 22.76 22.77 0.01  0.01 

	


 22.75 22.76 0.01  0.01 

	


 23.15 23.15 0.00  0.01 

	

	


 23.33 23.33 0.00  0.00 

	


 23.69 23.69 0.00  0.01 

	


 24.06 24.06 0.00  0.01 



	
 20.79 20.79 0.00  0.00 

	
	
	

 19.45 19.45 0.00  0.00 

	
	
	

 20.29 20.29 0.00  0.00 

	

	
	

 21.23 21.23 0.00  0.01 

	

	
	


 24.04 24.04 0.00  0.01 

	

	


 22.54 22.54 0.01  0.01 
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Figure 4-6 EIC chromatograms of glycosylated products. (A) The EIC chromatograms of 
Hex-Xyl-R, Hex(S)-Hex-Xyl(P)-R, HexA(S)-Hex-Hex-Xyl-R, S+HexNAc-HexA-Hex-Hex-Xyl-R, 
(HexNAc-HexA)2-Hex-Hex-Xyl-R, and NeuAc-Hex-(NeuAc)HexNAc-HexA-Hex-Hex-Xyl-R. m/z 
values and charges of the precursor ions are described in the figure. (B) The EIC chromatograms of 
Hex-Xyl-R enlarged at 8.45 min and (C) those of (HexNAc-HexA)2-Hex-Hex-Xyl-R at 23 min. The 
green and red lines indicate products of the light and heavy primers, respectively. 
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Next, the priming abilities of the primers were confirmed because differences 
in priming abilities may represent a bias in the quantification results. The same volumes 
of “light” and “heavy” media were mixed, processed and analyzed by LC–MS. In 
Figure 4-7, peak areas of several glycosylated products observed in “light” medium 
were plotted relative to those of “heavy” medium. The graph shows good linearity, with 
a slope of about 0.99. This result indicates that the primers have very similar priming 
abilities. Taking into consideration that the heavy products are used as internal 
standards, the priming abilities do not affect the quantification results. 
 
Moreover, the linearity and quantification accuracy of the method were 
examined using mixtures of light and heavy media at ratios of 1:1, 1:2.5, 1:5, 1:7.5 and 
1:10. The mixed medium was subjected to solid phase extraction and then analyzed by 
LC–MS. Figure 4-8 shows graphs of the relative peak areas (light/heavy) of some 
Figure 4-7 Correlation of the peak areas of light products to heavy products. The inset enlarges 
the region with small peak areas. 
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glycosylated products relative to the theoretical ratio. The graphs show good linearity 
over the tested range, although the observed ratios were somewhat smaller than the 
theoretical ratios. The result is probably attributable to the differences in the total 
concentrations of glycosylated products, since when the media were harvested, the 
plates or wells were washed with a small amount of PBS and the solution was pooled 
with the media. Given that the glycosylated products elongated on the heavy primer 
would be used as internal standards, the plot showed sufficient linearity for comparative 
quantification of glycosylated products. 
 
 
4.3.4 Method validation using GAG biosynthesis inhibitors 
To validate the method, a GAG inhibition assay was carried out to estimate 
the relative amounts of glycosylated products elongated in NHDF cells incubated with 
Figure 4-8 Linearity of the method at ratios of 1:1, 1:2.5, 1.5, 1:7.5, and 1:10. (A) Pentasaccharides
(HexNAc-HexA-Hex-Hex-Xyl-R). (B) Phosphorylated pentasaccharides 
(HexNAc-HexA-Hex-Hex-Xyl(P)-R). (C) Sulfated tetrasaccharides (HexA(S)-Hex-Hex-Xyl-R). 
(D) Sialylated trisaccharides (NeuAc-Hex-Xyl-R). 
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GAG biosynthesis inhibitors. As GAG biosynthesis inhibitors, azaserine, brefeldin A, 
genistein, and rhodamine B were chosen. Azaserine is an inhibitor of 
glutamine:fructose-6-phosphate amidotransferase, which is a key enzyme in the 
hexosamine biosynthetic pathway (HBP).82,83 Brefeldin A is an inhibitor that interferes 
with glycoprotein transport from the ER to the Golgi apparatus during glycan 
biosynthesis.53 Rhodamine B is a nonspecific inhibitor that reduces the expression of 
glycosyltransferases related to GAG biosynthesis.84,85 Genistein is a tyrosine kinase 
inhibitor for the epidermal growth factor receptor, which regulates downstream gene 
expression related to GAG biosynthetic enzymes.86 
 
As shown in Figure 4-1C, NHDF cells were incubated in medium containing 
each inhibitor (10 M or 100 M) and light primer (25 M). NHDF cells were also 
incubated with medium containing the heavy primer (25 M). After 3 days, the media 
were collected and equal volumes of both media were mixed. The glycosylated products 
were extracted, and then analyzed by LC–MS. Individual peak areas of the elongated 
products on the light primer were normalized to those on the heavy primer.  
 
Figure 4-9 shows the comparison of the relative amounts of the 
heptasaccharide ((HexNAc-HexA)2-Hex-Hex-Xyl-R_2). Without correction by the 
internal standard, the relative amounts of the heptasaccharide between the control and 
GAG biosynthesis inhibitors were not significantly different (Figure 4-9A), which was 
attributable to the large standard deviation of the control sample. In contrast, the relative 
amounts of the heptasaccharide between the control and GAG biosynthesis inhibitors 
were significantly different when corrected by the internal standard (Figure 4-9B). This 
result indicates that the established method can effectively reveal differences in GAG 
biosynthesis activity using GAG inhibitors. 
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The comparative results of the detected oligosaccharides are shown in Table 
4-5 and Figure 4-10. The result was able to clarify differences in the relative amounts of 
glycosylated products obtained from each medium containing the GAG inhibitors. As 
expected, the relative amounts of most glycosylated products were decreased in the 
genistein- or rhodamine B-added medium in a dose-dependent manner. This indicates 
that the method can detect the inhibition of GAG biosynthesis using these two 
inhibitors. 
Figure 4-9 Comparison of the relative amounts of the heptasaccharide 
((HexNAc-HexA)2-Hex-Hex-Xyl-R_2). (A) The relative amounts were compared based on the peak 
area of the heptasaccharide elongated on the light primer. The individual relative amounts were 
calculated by dividing the peak area of each GAG inhibitor by the average of the peak areas of 
control samples. (B) The relative amounts were compared based on the relative peak areas, which 
were calculated by dividing the peak areas of the light primer products by those of the heavy primer
products. Relative amounts indicated in both graphs represent the mean values ± S. D. Asterisks 
indicate p < 0.05 (*), < 0.01 (**), < 0.001 (***) versus the control (n = 3 per condition). 
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Table 4-5 Comparative quantification of glycosylated products elongated with each GAG inhibitor. 
The relative amounts indicate the mean values obtained from three individual experiments, and those 
that are significantly different from that of the control sample are heatmapped (p < 0.05). 
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The relative amounts of products found in the brefeldin A-added medium 
showed a characteristic change. Disaccharides (Hex-Xyl-R and Hex-Xyl(P)-R) and a 
tetrasaccharide (HexA-Hex-Hex-Xyl-R) were clearly increased, although glycosylated 
products longer than pentasaccharides were obviously decreased (Figure 4-10). This 
result indicates that brefeldin A inhibits certain steps in the GAG biosynthesis pathway. 
For example, the accumulation of disaccharides indicates that brefeldin A inhibits 
secondary Gal addition catalyzed by GalT-II. Also, the accumulation of 
HexA-Hex-Hex-Xyl-R indicates inhibition of the HexNAc addition step. On the other 
hand, our result indicates that brefeldin A inhibited the synthesis of 
HexA-Hex-Hex-Xyl(P)-R. This phenomenon is consistent with the mode of action of 
brefeldin A, which inhibits anterograde vesicular transportation through the Golgi 
apparatus.50,53,87 It has been reported that brefeldin A inhibited CS/DS biosynthesis but 
not HS biosynthesis.88 The report concluded that HS biosynthetic enzymes are localized 
in the ER and proximal Golgi apparatus. Hence, the tetrasaccharide 
Figure 4-10 Linkage tetrasaccharide biosynthetic pathway elongated on the light primer. The closed 
circles and bold arrows indicate the GAG intermediates biosynthesis pathway. The open circles and 
dashed arrows indicate the competitive pathway to synthesize sialylated and other glycosylated 
products. The bar graphs placed under the circles show the relative amounts of glycosylated 
products. Relative amounts indicated in the graphs represent the mean values ± S. D. Asterisks 
indicate p < 0.05 (*), < 0.01 (**), < 0.001 (***) versus the control (n = 3 per condition). 
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HexA-Hex-Hex-Xyl-R could be considered as an HS biosynthesis precursor, indicating 
the reason for HexA-Hex-Hex-Xyl-R accumulation by brefeldin A. In contrast, 
HexA-Hex-Hex-Xyl(P)-R is considered to be a CS/DS biosynthesis precursor and is 
suppressed by brefeldin A, because it has been demonstrated that xylose phosphatase 
and chondroitin N-acetylgalactomaminidase-1 are co-localized and work in harmony.15 
In this context, our results are consistent with the mode of action of brefeldin A. 
 
Unlike the above three inhibitors, azaserine exhibited a completely different 
effect on GAG chain elongation. Surprisingly, azaserine increased most of the GAG 
related oligosaccharides in a dose-dependent manner. In addition, the relative amounts 
of sialylated oligosaccharides were decreased in azaserine-added medium. These two 
results cannot be explained by the known mode of action of azaserine. One hypothesis 
to explain this effect is that azaserine might specifically inhibit certain steps in 
sialylation. Specific inhibition of sialylation would reduce adenosine triphosphate 
(ATP) consumption, and more ATP could be utilized for GAG biosynthesis. If 
sufficient amounts of hexosamine had been supplied, GAG chain elongation might be 
increased even in azaserine-added medium. Supporting this hypothesis, it has been 
reported that GAG biosynthesis inhibition by 6-diazo-5-oxonorleucine, an HBP 
inhibitor, was rescued by glucosamine addition.89 This point can be clarified by 
confirming the amount of hexosamine in the medium and the rate-limiting step for 
GAG production in NHDF cells.  
 
According to this result, the comparative quantification method could 
demonstrate differences in the mode of action between the four GAG biosynthesis 
inhibitors, and is thus considered applicable to investigate the GAG biosynthetic 
mechanism and its regulation. 
 
4.4 Conclusion 
In this chapter, a novel quantitative method for glycomics using a stable 
isotope-labeled saccharide primer was demonstrated. The heavy saccharide primer, 
which is deuterium-labeled in its alkyl chain, primed glycosaminoglycan-type 
oligosaccharides the same as the light primer, and the pairs of elongated 
oligosaccharides were not resolved in HILIC separation. In applying this method, four 
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GAG biosynthesis inhibitors were examined and their effects on GAG biosynthesis 
were compared. The result clearly indicated that this method could identify differences 
in the mode of action of the GAG inhibitors.  
 
In this study, some positional isomers of sulfated GAGs were detected, even 
though the sulfation position of these isomers has not been determined. The sulfation 
position in GAG biosynthesis is considered to be an important factor in determining the 
GAG type, length and number attached to PGs. Therefore, quantitative and qualitative 
analyses of the sulfated isomers will contribute to the investigation of the GAG 
biosynthetic mechanism. 
 
The saccharide primers can be applied to comparative glycomics study as well 
as to the preparation of analytical standard libraries to examine the activities of various 
enzymes related to GAG catabolism. These libraries could be applied to the diagnosis of 
GAG metabolic diseases like mucopolysaccharidosis (MPS), since the activity of GAG 
degradation enzymes can be easily measured by comparison of the glycosylated 
products with or without GAG enzymatic treatment. Therefore, the quantification 
strategy represents a new tool for comparative glycosaminoglycomics using cultured 
cells and tissues, not only in the search for GAG biomarkers, but also to construct GAG 
oligosaccharide libraries for MPS diagnostics. 
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Chapter 5  
Evaluation of Exogenous GAG Effects on GAG Biosynthesis 
 
5.1 Introduction 
Exogenously administration of GAGs has been used in therapeutic 
applications such as visco-supplementations for knee osteoarthritis. It is well-known 
that GAGs not only work as shock absorber or lubricant in synovial fluid, but also 
directly affect chondrocytes through their specific receptors such as CD44 and 
ICAM-I.1,90,91 In addition, there are some studies that demonstrate that exogenous GAG 
affects endogenous GAG production in several cells and tissues.92–95 These results 
suggest that GAGs work as signaling molecules that regulate ECM components 
autocrinally. Since the structures of GAGs generally affect the affinity to their receptors, 
it is also assumed that the autocrinal effect is regulated by the structural feature of the 
exogenous GAGs. In most cases, the effects of exogenous GAGs have been examined 
by metabolic labeling experiment using radioisotopes. Although both the sensitivity and 
selectivity of the experiments were sufficiently high, the structural elucidation of the 
endogenously synthesized GAG had been conducted insufficiently. As described in 
chapter 1, GAG biosynthesis is closely related to the production of the intermediates 
including the phosphorylated linkage tetrasaccharide. Therefore, exogenously added 
GAGs are assumed to control the endogenously produced GAG intermediates. 
 
In chapter 4, the comparative quantification method for GAG intermediates 
elongated on the saccharide primers was established. In this chapter, the comparative 
quantification method was applied to confirm the effect of exogenous GAGs on the 
biosynthetic ability of NHDF cells for GAGs and GAG intermediates. 
 
 
5.2 Materials and methods 
5.2.1 Materials 
CS-C and CS-E were purchased from Seikagaku Corporation (Tokyo, Japan). 
Heparin was purchased from Wako Pure Chemical Industries (Osaka, Japan). Cells, 
media, and other reagents were the same as described in Chapter 4. Unless otherwise 
stated, reagents and solvents were used without purification. 
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5.2.2 Comparative quantification of elongated oligosaccharides 
Priming of elongated oligosaccharides, relative quantification of the elongated 
oligosaccharides, LC–MS/MS analysis, and data analysis were carried out according to 
the method described in Chapter 4. In brief, NHDF cells (4 × 105) were seeded onto the 
wells of a six-well plate and cultured for 18 h to 80 % confluence. After the cells were 
washed with PBS, they were incubated for 3 days with 1 mL of DMEM without phenol 
red and containing both 25 M of the light primer and 500 g/mL of each GAG. The 
media and cells were then harvested, the cells were removed by centrifugation, and then 
the medium was transferred to a 5 mL tube. The internal standards, glycosylated 
products elongated on the heavy primer, were obtained from the medium that was 
harvested from the NHDF cells (1 × 106) and incubated in a 15 cm dish with the heavy 
primer. The collected medium was stored at 80 °C until use. A 0.75-mL aliquot of the 
“heavy” medium was added to the same volume of the “light” medium collected from a 
well and then mixed. The mixed media were subjected to the SPE, and then analyzed by 
LC–MS.  
 
5.3 Results and discussion 
 To confirm the effects of exogenous GAGs, CS-C, CS-E, and heparin were 
chosen as samples for examination. CS-C, mainly sulfated on 6-O-groups on GalNAc 
residues, is easily available because of its wide commercialization. CS-E is a highly 
sulfated CS and has demonstrated many biological activities such as interaction with 
growth factors.10,96,97 Heparin was chosen as a positive control since it is a typical highly 
sulfated GAG and is well-known for its biological activity. Structural features of these 
GAGs are described in Table 5-1. 
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Table 5-1 Weight-average molecular weight (Mw) and sulfur content of GAGs examined in the 
study. (*) Determined by gel filtration chromatography. (**) Determined by an in-house established 
method using capillary electrophoresis. (***) Quoted from Lin et al. 98  
GAGs Mw* (kDa) Sulfur contents (%) 
CS-C 45.5 7.42** 
CS-E 97.6 9.43** 
Heparin 15.6 12.20*** 
 
The result of comparative quantification is shown in Table 5-2 and Figure 5-1. 
Compared with those of the control samples, the relative amounts of elongated glycans 
in exogenous added GAG samples increased. In particular, CS-E considerably increased 
the relative amounts of the glycosylated products. This result indicates that certain 
exogenous GAGs could stimulate the biosynthesis of glycans including GAGs in 
fibroblasts. Kawamura et al. documented how exogenous CS-E enhanced endogenous 
GAG production and how it promoted chondrogenic differentiation of ATDC5, which is 
a chondrogenic cell line derived from mouse teratocarcinoma.92 They reported in the 
paper that CS-A and CS-C, which are low-sulfated GAGs, did not show significant 
enhancement of endogenous GAG production. The result indicates that the sulfated 
pattern could strongly affect the enhancement of endogenous GAG production. Albeit 
the cells used in the studies were different, the results are consistent with those in 
previous studies. Therefore, the comparative quantification method using stable-isotope 
saccharide primer is applicable to the evaluation of the effect of exogenous GAGs on 
endogenous GAG production. 
 
In contrast, heparin did not significantly increase the glycosylated products, 
although the sulfur content of heparin was much higher than that of CS-E. This 
indicates that the effect observed in this study mainly depends on certain structural 
features, such as sulfation pattern and molecular weight, rather than on the polyanionic 
nature of GAG. To clarify the structure–activity relationship of the exogenous and 
endogenous GAG, more studies using structurally determined GAGs are needed. 
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Table 5-2 Comparative quantification of glycosylated products elongated with each GAG. The 
relative amounts indicate the mean values obtained from three individual experiments, and those that 
are significantly different from that of the control sample are heatmapped (p < 0.05). 
 
 
	
   
		
   
	
   
		
   
		
   
		
   
			
   
		
   
				
   
			
   
			
   
				
   
			
   
			
   
				
   
				
   
				
   
				
   
				
   
				
   
					
   
				
   
				
   
						
   
				
   
				
   
				
   
					
   
					
   
						
   
							
   
						
   
  	

Glycosylated products CS-C CS-E Hep
Relative amounts
Chapter 5 
 
89 
 
 
 
5.4 Conclusion 
By applying relative quantification strategy using an isotope-labeled 
saccharide primer, the effect of exogenous GAG on endogenous GAG production could 
be evaluated. Endogenous GAG production was increased with highly sulfated GAGs 
such as CS-E. Compared with CS-C and heparin, CS-E significantly increased the 
relative amounts of oligosaccharides elongated on the primer. This result indicates that 
the sulfur contents, which represents the anion charge amounts in the GAG chain, as 
well as the structure of GAGs including repeating disaccharide units and sulfated 
positions, affects GAG biosynthesis. Further investigation on the relationship between 
exogenous and endogenous GAG would lead to an understanding of both proliferation 
and differentiation behaviors due to the GAG autocrine mechanism. 
Figure 5-1 CS-E increases GAG biosynthetic intermediates elongated on the primer. The closed
circles and bold arrows indicate the GAG intermediates in the biosynthetic pathway. The open 
circles and dashed arrows indicate the competitive pathway for the synthesis of sialylated and other
glycosylated products. The bar graphs placed under the circles show the relative amounts of 
glycosylated products. Relative amounts indicated in the graphs represent the mean values ± S. D. 
Asterisks indicate p < 0.05 (*), < 0.01 (**).  
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Chapter 6  
Concluding remarks 
The glycomics research field has expanded in recent decades in line with the 
development of quantitative and qualitative analysis technologies for glycans. Although 
GAGs, which are one of the main components of ECM and pericellular matrices, have 
been reported to play key roles in a wide variety of biological phenomena, glycomics 
techniques for GAGs are still in their infancy. The aim of this study is to discover a 
-xyloside suitable for in-depth analysis of GAG biosynthetic intermediates in cells and 
to establish a comparative quantification method for applying the saccharide primer 
method. 
 
In chapter 1, the structures, biological activities, and analytical methods for GAGs 
were summarized. Additionally, the aim of the study was described. 
 
In chapter 2, the synthetic scheme for -xylosides that have O-xylosyl amino acid 
residues was established using chemoemzymatic condensation.  
 
In chapter 3, the priming ability of the four - xylosides in NHDF cells was studied. 
By optimization of sample preparation and LC–MS/MS conditions, the difference in the 
priming ability and GAG intermediate oligosaccharides was clarified. 
  
In chapter 4, a comparative quantification method for elongated oligosaccharides 
using stable-isotope-labeled saccharide primer was established. The method was 
validated using GAG biosynthesis inhibitors. The result clearly indicates that the 
method could reveal differences in the mode of action of the examined GAG inhibitors. 
 
In chapter 5, the effect of exogenous sulfated GAGs on endogenous GAGs 
production was examined by the comparative quantification method. The result reveals 
that certain sulfated GAGs stimulate NHDF cells to increase endogenous GAG 
production. 
 
In the thesis, the feasibility of saccharide primer method for quantitative and 
qualitative GAG-omics study was demonstrated. To enable convenient synthesis and 
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expand the versatility of structural development of -xylosides, chemical synthesis 
using chemoenzymatic condensation was established. The four derivatives could be 
synthesized through protocols of only three steps, and the relationship between the 
GAG chain priming ability and aglycone structure of the -xylosides was clarified. In 
addition, the relative quantification method using the stable-isotope-labeled -xyloside 
was established. This method made it possible to reveal the inhibition mechanisms of 
the GAG biosynthesis inhibitor and to clarify a novel effect of azaserine, which inhibit 
sialic acid biosynthesis without GAG biosynthesis inhibition. Finally, the method was 
applied to evaluate the effect of exogenous GAGs on endogenous GAG production. The 
effect of exogenous CS-E on endogenous GAG production was successfully confirmed 
by the established method. The result indicates that the exogenous sulfated GAGs 
up-regulate GAG biosynthesis including GAG intermediates.  
  
 GAGs contribute to various biological events related to cell–cell interactions. 
Understanding GAG biosynthesis mechanisms and the structure–activity relationship of 
the GAGs on the GAG autocrine system will open a new avenue for GAG-driven drug 
discovery. I believe that the method developed in the study will shed new light on the 
GAG-omics research field. 
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Apo B/E apolipoprotein B/E 
ATP adenosine triphosphate 
BSA bovine serum albumin 
C-ABC chondroitinase ABC 
C-ACII chondroitinase ACII 
CE collision energy 
CMP cartilage matrix protein 
cps count per second 
CS chondroitin sulfate 
DBAA dibutylammonium acetate 
DIEA N,N-diisopropylethylamine 
DMEM Dulbecco's modified Eagle's medium 
DMF N,N-dimethylformamide 
DMT-MM 
4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium 
chloride 
DS dermatan sulfate 
ECM extracellular matrix 
EDCI 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride 
EDTA ethylenediaminetetraacetic acid 
EGF epidermal growth factor 
EIC extracted ion chromatogram 
ER endoplasmic reticulum 
ESI electrospray ionization 
Ext exostosin 
Extl-1/2/3 exostosis-like gene 1/2/3 
FA formic acid 
FAM20B 
GAG xylosylkinase-named family with sequence similarity 20, 
member B 
FGF fibroblast growth factor 
FGFR fibroblast growth factor receptor 
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GAG glycosaminoglycan 
Gal galactose 
GalNAc N-acetylgalactosamine 
GalT galactosyltransferase 
GlcA glucuronic acid 
GlcNAc N-acetylglucosamine 
Gly glycine 
Gly-(Xyl)Thr-C12 N-lauroyl -O-- D-xylopyranosyl-L-threonyl glycinamide 
Gly-(Xyl)Ser-C12 N-lauroyl -O-- D-xylopyranosyl-L-serinyl glycinamide 
GM-CSF granulocyte macrophage colony-stimulating factor 
GRIP-1 GDSL esterase/lipase 1  
HB-EGF heparin-binding EGF-like growth factor 
HB-GAM heparin-binding growth-associated molecule 
HBP hexosamine biosynthetic pathway 
HDL high density lipoprotein 
Hep heparin 
Hex hexose 
HexA hexuronic acid 
HexNAc N-acetylhexosamine 
HGF hepatocyte growth factor 
HILIC hydrophilic interaction chromatography 
HOBt 1-hydroxybenzotriazole 
HPLC high-performance liquid chromatography 
HRMS high resolution mass spectrometory 
HS heparan sulfate 
ICAM-1 intercellular adhesion molecule-1 
IdoA iduronic acid 
IGF insulin-like growth factor 
IP-10 IFN--inducible protein of 10 kDa 
KS keratan sulfate 
LC liquid chromatoraphy 
LDL low density lipoprotein 
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MAC-1 macrophage-1 antigen 
MMP7 matrix metalloproteinase-7 
MPS mucopolysaccharidosis 
MS mass spectrometry 
MS/MS tandem mass spectrometry 
MT3-MMP membrane-type-3 matrix metalloproteinase 
N-CAM neural cell adhesion molecule 
NDST N-deacetylase-N-sulfotransferase 
NeuAc N-acetylneuraminic acid 
NHDF normal human dermal fibroblasts 
NMR nuclear magnetic resonance 
PDGF platelet-derived growth factor 
PECAM-1 platelet endothelial cell adhesion molecule-1 
PF-4 platelet factor 4 
PG proteoglycan 
pNP para-nitrophenol 
PTN pleiotrophin 
PyBOP 
(benzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate  
RANTES regulated on activation, normal T cell expressed and secreted 
SD standard deviation 
SDF stromal cell derived factor 
Ser serine 
SF scatter factor 
SLC solute carrier 
SPE solid phase extraction 
TBA tetrabutylammonium 
TFA trifluoroacetic acid 
TGF transforming growth factor  
THF tetrahydrofuran 
Thr threonine 
TMSOTf trimethylsilyl trifluoromethanesulfonate 
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TNF tumor necrosis factor 
TPA tissue plasminogen activator 
VEGF vascular endothelial growth factor 
Xyl xylose 
Xyl-C12 dodecyl xyloside 
Xyl-Thr-C12 N-lauroyl-O--D-xylopyranosyl-L-threonamide 
Xyl-Ser-C12 N-lauroyl-O--D-xylopyranosyl-L-serinamide 
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